



HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT 2023



PHRAMONGKUTKLAO HOSPITAL

ARMY MEDICAL DEPARTMENT
MINISTRY OF DEFENCE
THAILAND

PHRAMONGKUTKLAO HOSPITAL
EXCELLENT
CENTER
OF CANCER CARE

2023

Title	Phramongkutklao Hospital Cancer Registry Report 2023
Editorial Board	Naiyarat Prasongsook, M.D. Chairman of cancer Registry Committee, Chairman Excellent Center of Cancer Care. Kritsada Srithanaphakarangkul, M.D. Chairman of Cancer of the Data Information committee
Published by	Clinical Epidemiology Unit and Oncology Department, Phramongkutklao Hospital 315 Chalermprakiet Building, Ratchawithi Road, Ratchathewi District, Thung Phaya Thai Subdistrict. Bangkok 10400 Tel. : 02763 3925, 02763 3047
Published Edition Physical	2024 Sixteenth 74 pages



EXCELLENT CENTER OF CANCER CARE

HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT

2023

Phramongkutklo Hospital
Royal Thai Army Medical Department
Ministry of Defence
Bangkok, Thailand

Edited By
Y. Tanapat and K. Sriphanaphakarangkul

Edition : December 2023

MESSAGE FROM DIRECTOR OF PHRAMONGKUTKLAO HOSPITAL



The Phramongkutkiao Hospital is proud to present the Cancer Registry Report 2022. The report collects information on all new cancer cases. Data collected include the clinical characteristics of the cancer (site, histology, behavior, grade, extent of disease) and treatment details on the cancer patient. The registry has a comprehensive quality assurance program in place to ensure that the data are complete, accurate and timely.

I would like to thank all our collaborators for their dedication in providing data presented in this volume. I would like to express my gratitude to the devoted staffs of cancer registry in all cancer units for the immense amount of work that has been done in preparation of the statistics and graphics for this volume.

Thamrongroj Temudom Maj. Gen.
Director General of Phramongkutkiao Hospital






INTRODUCTION

The Phramongkutklao Hospital Cancer Registry Report 2022 is a hospital-based cancer registry of new cancer patients initially diagnosed or initially treated at Phramongkutklao Cancer Center from January 1, 2022, to December 31, 2021. All new cancer patients registered during the mentioned period were treated at the various Cancer Units under The Excellent center of Cancer Care, Phramongkutklao Hospital. Patients were either primarily diagnosed or referred from army hospitals (under supervision of the Royal Thai Army Medical Department) as well as public and private hospitals. The objective of this is to report new cancer patients regarding method of diagnosis, pathological types, staging, behavior, grading, extension, and primary treatment modalities. Phramongkutklao Hospital has initiated a hospital cancer registry system based on the existing hospital data management system since 2009. This system has enabled physicians and nurses taking care of cancer patients to update patient information on the cancer registry at Cancer Units on a real-time basis. Thus, information obtained can be corrected and updated by persons in charge of patient care at the time of the patient's hospital visit. This process should contribute to the validity of information in the Cancer Registry.

This Cancer Registry Report would not be possible without the dedicated input of data from the staff of the Cancer Clinics and the Cancer Units from different departments at Phramongkutklao Cancer Center.



Assist. Prof. Naiyarat Prasongsook, M.D., M.S., COL.
Chairman Cancer Registry Committee
Phramongkutklao Cancer Center

EXCELLENT CENTER OF CANCER CARE PHRAMONGKUTKLAO HOSPITAL

1.	Maj.Gen.Thamrongroj	Temudom	Consultant
2.	Col. Pariyanan	Jaruchinda	Consultant
3.	Col. Rachata	Lumkul	Consultant
4.	Col. Kasan	Seetalarom	Consultant
5.	Col. Naiyarat	Prasongsook	Chairman of Administor Committee
6.	Col. Sukchai	Satthaporn.	Member
7.	Col. Chinakrit	BoonyaUssadorn	Member
8.	Col. Satit	Siriboonrid	Member
9.	Col. Sirinthip	Songwutwichai	Member
10.	Col. Chanchai	Traivaree	Member
11.	Col. Phutsapong	Srisawat	Member
12.	Lt.Col. Sithapan	Munjupong	Member
13.	Col. Kristsanamon	Rittiluechai	Member
14.	Lt.Col. Chonlada	Laoruagroj	Member
15.	Col. Vana	Sangsasri	Member
16.	Lt.Col. Jarey	Ketsirichai	Member
17.	Lt.Col. Siriwimon	Saichaemchan	Member
18.	Lt.Col. Watcharaporn	bourchom	Member
19.	Lt.Col. Kanya	Ketkong	Member
20.	Lt.Col. Nattapoang	Binsri	Member
21.	Lt.Col. Chalinee	Monseereenusorn	Member
22.	Lt.Col. Usa	Rittitada	Member
23.	Lt.Col. Supicha	Wongphun	Member



EXCELLENT CENTER OF CANCER CARE PHRAMONGKUTKLAO HOSPITAL

24.	Lt.Col. Kannadit	Prayongratana	Member
25.	Maj. Suvicha	Khampunnip	Member
26.	Maj. Sujitra	Shoolerd	Member
27.	Maj. Weerawan	Kaesai	Member
28.	Maj. Piyanuch	Srisuk	Member
29.	Maj. Nongnut	Seedapalee	Member
30.	Lt.Col. Rapeeporn	Kanchanapachana	Member
31.	Maj. Chetsuda	Khwanakorn	Member
32.	Capt. Sutipat	Pairojboriboon	Member
33.	Lt. Chatchanin	Ajalanond	Member
34.	Dr. Panjawit	Wuttipanich	Member
35.	Maj. wanvipa	Malaithong	Member
36.	Capt. Supittha	Tongpit	Member
37.	Maj. Phapasi	Punphasoed	Member
38.	Col. Jariya	Ketkaeo	Member
39.	Col. Waniknan	Hatsadin	Member
40.	Capt. Patcharaporn	lamsuwan	Member
41.	Capt. Atcharaporn	Sittichai	Member

CANCER REGISTRY STAFF

1.	Miss Rungthip	Boonyai	B.Com. (Computer)
2.	Miss Chawanphat	Udomphon	B.Sc. (Statistics)



TABLE OF CONTENTS

Title		
List of tables:		Page
Table 1	Distribution of new cancer patients by gender: 2023	1
Table 2	Number of all new patients: 2012-2023	2
Table 3	Ten leading primary sites of new cancer patients by gender: 2023	3
Table 4	Ten leading primary sites of new cancer patients in male: 2023	4
Table 5	Ten leading primary sites of new cancer patients in female: 2023	5
Table 6	Distribution of new cancer patients by age group and gender: 2023	6
Table 7	Distribution of new cancer patients by stage and gender: 2023	7
Table 8	Distribution of new cancer patients by grade and gender : 2023	8
Table 9	Distribution of new cancer patients by extension and gender: 2023	9
Table 10	Distribution of new cancer patients by method and gender: 2023	10
Table 11.1	Distribution of new cancer patients by treatment modalities and gender: 2023	11
Table 11.2	Distribution of new cancer patients by treatment modalities and gender: 2023	12
Table 12	Distribution of new cancer patients by treatment unit and gender: 2023	13
Table 13	Distribution of new cancer patients by status 2023	14
Table 14	Distribution of new cancer patients by follow up status and gender 2023	14
Table 15	Distribution of new military personnel cancer patients by age group and gender: 2023	15
Table 16	Distribution of new cancer patients by rank and gender: 2023	16
Table 17	Distribution of new childhood cancer patients (age 0-19) by age group and gender: 2023	17
Table 18	Distribution of new childhood cancer patients (age 0-19) by primary sites: 2023	17
Table 19	Distribution of new childhood cancer patients (age 0-19) by treatment modalities and gender: 2023	18
Table 20	Distribution of new childhood cancer patients (age 0-19) by method and gender: 2023	18
Table 21	Distribution of new childhood cancer patients (age 0-19) by type of extension and gender: 2023	19
Table 22	Distribution of new childhood cancer patients (age 0-19) by follow up and gender: 2023	19
Table 23	Number of new cancer patient stage and gender: 2023	20

TABLE OF CONTENTS

Title		
List of tables:		Page
Description of the leading site of cancers ordinal 1-3		
1. Colon and rectum cancer		
Table 24	Trend of colon and rectum cancer in Phramongkutklao hospital: 2012-2023	27
Table 25	Distribution of new colon and rectum cancer patients by age group and gender: 2023	28
Table 26	Distribution of new colon and rectum cancer patients by stage and gender: 2023	29
Table 27	Distribution of new colon and rectum cancer patients by method and gender: 2023	30
Table 28	Distribution of new colon and rectum cancer patients by extension and gender: 2023	30
Table 29	Distribution of new colon and rectum cancer patients by treatment modalities and gender: 2023	31
Table 30	Distribution of new colon and rectum cancer patients by follow up status and gender: 2023	31
2. Trachea, bronchus, and lung cancer		
Table 31	Trend of trachea, bronchus, and lung cancer in Phramongkutklao hospital: 2012-2023	32
Table 32	Distribution of new trachea, bronchus and lung cancer patients by age group and gender: 2023	33
Table 33	Distribution of new trachea, bronchus and lung cancer patients by stage and gender: 2023	34
Table 34	Distribution of new trachea, bronchus and lung cancer patients by method and gender: 2023	35
Table 35	Distribution of new trachea, bronchus and lung cancer patients by extension and gender: 2023	35
Table 36	Distribution of new trachea, bronchus and lung cancer patients by treatment modalities and gender : 2023	36
Table 37	Distribution of new trachea, bronchus, and lung cancer patients by follow up status and gender: 2023	36
3. Breast cancer		
Table 38	Trend of breast cancer in Phramongkutklao hospital: 2012-2023	37
Table 39	Distribution of new breast cancer patients by age group and gender: 2023	38
Table 40	Distribution of new breast cancer patients by stage and gender: 2023	39
Table 41	Distribution of new breast cancer patients by method and gender: 2023	40
Table 42	Distribution of new breast cancer patients by extension and gender: 2023	40
Table 43	Distribution of new breast cancer patients by treatment modalities and gender: 2023	41
Table 44	Distribution of new breast cancer patients by follow up status and gender: 2023	41

TABLE OF CONTENTS

Title		
List of tables:		Page
Description of the leading site of cancers ordinal 4-6		
4. Thyroid cancer		
Table 45	Distribution of new Thyroid cancer patients by age group and gender : 2023	42
Table 46	Distribution of new Thyroid cancer patients by stage and gender : 2023	43
Table 47	Distribution of new Thyroid cancer patients by method and gender : 2023	44
Table 48	Distribution of new Thyroid cancer patients by extension and gender : 2023	44
Table 49	Distribution of new Thyroid cancer patients by treatment modalities and gender : 2023	45
Table 50	Distribution of new Thyroid cancer patients by follow up status and gender : 2023	45
5. Prostate gland		
Table 51	Distribution of new Prostate gland cancer patients by age group and gender: 2023	46
Table 52	Distribution of new Prostate gland cancer patients by stage and gender: 2023	47
Table 53	Distribution of new Prostate gland cancer patients by method and gender: 2023	48
Table 54	Distribution of new Prostate gland cancer patients by extension and gender: 2023	48
Table 55	Distribution of new Prostate gland cancer patients by treatment modalities and gender: 2023	49
Table 56	Distribution of new Prostate gland cancer patients by follow up status and gender: 2023	49
6. Liver and intrahepatic bile ducts cancer		
Table 57	Distribution of new Liver and intrahepatic bile ducts cancer patients by age group and gender: 2023	50
Table 58	Distribution of new Liver and intrahepatic bile ducts cancer patients by stage and gender: 2023	51
Table 59	Distribution of new Liver and intrahepatic bile ducts cancer patients by method and gender: 2023	52
Table 60	Distribution of new Liver and intrahepatic bile ducts cancer patients by extension and gender: 2023	52
Table 61	Distribution of new Liver and intrahepatic bile ducts cancer patients by treatment modalities and gender: 2023	53
Table 62	Distribution of new Liver and intrahepatic bile ducts cancer patients by follow up status and gender: 2023	53

TABLE OF CONTENTS

Title		
List of tables:		Page
Number of cases by age-group in sex		
Table 63	Distribution of new cancer in male by age - group: 2023	54
Table 64	Distribution of new cancer in female by age - group: 2023	55
Distribution of new cancer in by morphology and site: 2023		
Table 65	Distribution of new cancer patients by morphology and site: 2023	56
Distribution of new cancer patients: 2019-2023		
Table 66	Number of new cancer patients: 2019-2023	70
Table 67	Distribution of new cancer patients by follow up and gender: 2019-2023	71
Table 68	The leading primary sites of new cancer by gender: 2019-2023	71
Table 69	The leading primary sites of new cancer by follow up and gender: 2019-2023	72
Table 70	The 60 months survival time (median) top 6 by gender in 2019 - 2023	72

FIGURE OF CONTENTS

Title		
List of figures:		Page
Figure 1	All new cancer cases in Phramongkutklao hospital :2012-2023	1
Figure 2	Trend of number of all new cancer patients by gender :2012-2023	2
Figure 3	Ten leading primary sites of new cancer patients by gender: 2023	3
Figure 4	Ten leading primary sites of new cancer patients in male: 2023	4
Figure 5	Ten leading primary sites of new cancer patients in female: 2023	5
Figure 6	Distribution of new cancer patients by age group and gender: 2023	6
Figure 7	Distribution of new cancer patients by stage and gender: 2023	7
Figure 8	Distribution of new cancer patients by grade and gender: 2023	8
Figure 9	Distribution of new cancer patients by extension and gender: 2023	9
Figure 10	Distribution of new cancer patients by method and gender: 2023	10
Figure 11	Distribution of new cancer patients by treatment unit and gender: 2023	13
Figure 12	Distribution of new cancer patients by follow up status: 2023	14
Figure 13	Distribution of new military personnel cancer patients by age group and gender: 2023	15
Figure 14	Distribution of new cancer patients by rank and gender: 2023	16



FIGURE OF CONTENTS

Title		
List of figures:		Page
Description of the leading site of cancers ordinal 1-3		
1. Colon and rectum cancer		
Figure 15	Distribution of new colon and rectum cancer patients by age group and gender: 2023	28
Figure 16	Distribution of new colon and rectum cancer patients by stage and gender: 2023	29
Figure 17	Distribution of new colon and rectum cancer patients by extension and gender: 2023	30
2. Trachea, bronchus, and lung cancer		
Figure 18	Distribution of new trachea, bronchus and lung cancer patients by age group and gender: 2023	33
Figure 19	Distribution of new trachea, bronchus and lung cancer patients by stage and gender: 2023	34
Figure 20	Distribution of new trachea, bronchus and lung cancer patients by extension and gender: 2023	35
3. Breast cancer		
Figure 21	Distribution of new breast cancer patients by age group and gender: 2023	38
Figure 22	Distribution of new breast cancer patients by stage and gender: 2023	39
Figure 23	Distribution of new breast cancer patients by extension and gender: 2023	40
4. Thyroid gland		
Figure 24	Distribution of new Thyroid gland cancer patients by age group and gender: 2023	42
Figure 25	Distribution of new Thyroid gland cancer patients by stage and gender: 2023	43
Figure 26	Distribution of new Thyroid gland cancer patients by extension and gender: 2023	44
5. Prostate gland		
Figure 27	Distribution of new Prostate gland cancer patients by age group and gender: 2023	46
Figure 28	Distribution of new Prostate gland cancer patients by stage and gender: 2023	47
Figure 29	Distribution of new Prostate gland cancer patients by extension and gender: 2023	48
6. Liver and intrahepatic bile ducts cancer		
Figure 30	Distribution of new Liver and intrahepatic bile ducts cancer patients by age group and gender: 2023	50
Figure 31	Distribution of new Liver and intrahepatic bile ducts cancer patients by stage and gender: 2023	51
Figure 32	Distribution of new Liver and intrahepatic bile ducts cancer patients by extension and gender: 2023	52

FIGURE OF CONTENTS

Title		
List of tables:		Page
Number of cases by age-group in sex		
Distribution of the 60-month survival rate of cancers in : 2019-2023		
Figure 32	The 60 months survival rate (top 6) in 2019 – 2023	72
Figure 33	The 60 months survival rate (top 6) by male in 2019 – 2023	73
Figure 34	The 60 months survival rate (top 6) by Female in 2019 – 2023	74



2023 HOSPITAL-BASED CANCER REGISTRY ANNUAL REPORT



TABLE 1 DISTRIBUTION OF NEW CANCER PATIENTS BY GENDER : 2023	
Type of patients	Number of cases
Total new hospital patients	41,671 (100.0%)
Total new cancer patients	1,825 (4.38%)
Gender distribution of cancer	
• Male	1,825 (4.38%)
• Female	1,825 (4.38%)

FIGURE 1: ALL NEW CANCER CASE IN PHRAMONGKUTKLOA HOSPITAL: 2012 – 2023






TABLE 2 NUMBER OF ALL NEW PATIENTS : 2012 – 2023							
Years	New patient Number	New cancer case Number	Case Percent	Male		Female	
				Number	Percent	Number	Percent
2555 (2012)	58,244	1,898	3.26	985	1.69	913	1.57
2556 (2013)	66,151	1,801	2.72	897	1.36	904	1.37
2557 (2014)	68,306	1,856	2.72	947	1.39	909	1.33
2558 (2015)	55,484	1,536	2.77	801	1.44	735	1.32
2559 (2016)	59,191	1,771	2.99	881	1.49	890	1.50
2560 (2017)	58,320	1,539	2.64	779	1.34	760	1.30
2561 (2018)	55,771	1,666	2.99	886	1.59	780	1.40
2562 (2019)	57,049	1,720	3.01	885	1.55	835	1.46
2563 (2020)	42,412	1,608	3.79	800	1.89	808	1.91
2564 (2021)	46,210	1,526	3.30	771	1.67	755	1.63
2565 (2022)	47,768	1,702	3.56	822	1.72	880	1.84
2566 (2023)	41,671	1,825	4.38	912	2.19	913	2.19

FIGURE 2: TREND OF NUMBER OF ALL NEW PATIENTS BY GENDER: 2012 – 2023






TABLE 3 TEN LEADING PRIMARY SITES OF NEW CANCER PATIENTS BY GENDER : 2023							
Ordinal	Primary site	Male		Female		Total	
		Number	Percent	Number	Percent	Number	Percent
1	Colon and Rectum	147	16.1	102	11.2	249	13.6
2	Trachea, bronchus and lung	108	11.8	88	9.6	196	10.7
3	Breast	2	0.2	187	20.5	189	10.4
4	Thyroid gland	33	3.6	118	12.9	151	8.3
5	Prostate gland	146	16.0	0	0.0	146	8.0
6	Liver and intrahepatic bile ducts	98	10.7	28	3.1	126	6.9
7	Non-Hodgkin's lymphoma	38	4.2	36	3.9	74	4.1
8	Cervix	0	0.0	59	6.5	59	3.2
9	Uterus	0	0.0	51	5.6	51	2.8
10	Leukemia	30	3.3	19	2.1	49	2.7

FIGURE 3: TEN LEADING PRIMARY SITES OF NEW CANCER PATIENTS BY GENDER: 2023






TABLE 4 TEN LEADING PRIMARY SITES OF NEW CANCER PATIENTS IN MALE : 2023			
Ordinal	Primary site	Number	Percent
1	Colon and Rectum	147	16.10
2	Prostate gland	146	16.00
3	Trachea, bronchus and lung	108	11.80
4	Liver and intrahepatic bile ducts	98	10.70
5	Non-Hodgkin's lymphoma	38	4.20
6	Bladder	34	3.70
7	Thyroid gland	33	3.60
8	Leukemia	30	3.30
9	Skin	24	2.60
10	Kidney, renal pelvis and ureter	21	2.40

FIGURE 4: TEN LEADING PRIMARY SITES OF NEW CANCER PATIENTS IN MALE: 2023







TABLE 5 TEN LEADING PRIMARY SITES OF NEW CANCER PATIENTS IN FEMALE : 2023			
Ordinal	Primary site	Number	Percent
1	Breast	187	20.50
2	Thyroid gland	118	12.90
3	Colon and Rectum	102	11.20
4	Trachea, bronchus and lung	88	9.60
5	Cervix	59	6.50
6	Uterus	51	5.60
7	Non-Hodgkin's lymphoma	36	3.90
8	Ovary	33	3.60
9	Liver and intrahepatic bile ducts	28	3.10
10	Skin	22	2.40

FIGURE 5: TEN LEADING PRIMARY SITES OF NEW CANCER PATIENTS IN FEMALE: 2023





HOSPITAL-BASED CANCER REGISTRY 2023

ANNUAL REPORT

TABLE 6		DISTRIBUTION OF NEW CANCER PATIENTS BY AGE GROUP AND GENDER : 2023				
Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
0 – 4	4	0.4	3	0.3	7	0.4
5 – 9	3	0.3	3	0.3	6	0.3
10 – 14	2	0.2	4	0.4	6	0.3
15 – 19	2	0.2	2	0.2	4	0.2
20 – 24	16	1.8	8	0.9	24	1.3
25 – 29	13	1.4	27	3.0	40	2.2
30 – 34	20	2.2	33	3.6	53	2.9
35 – 39	19	2.1	45	4.9	64	3.5
40 – 44	34	3.7	78	8.5	112	6.1
45 – 49	64	7.0	89	9.7	153	8.4
50 – 54	73	8.0	97	10.6	170	9.3
55 – 59	104	11.5	118	12.9	222	12.2
60 – 64	123	13.5	95	10.4	218	11.9
65 – 69	138	15.1	100	11.0	238	13.1
70 – 74	121	13.3	85	9.4	206	11.3
75 – 79	86	9.5	45	4.9	131	7.2
80 – 84	44	4.8	51	5.6	95	5.2
85 +	46	5.0	30	3.4	76	4.2
Total	912	100.0	913	100.0	1825	100.0

Majority of cases

FIGURE 6: DISTRIBUTION OF NEW CANCER PATIENTS BY AGE GROUP AND GENDER: 2023







TABLE 7 DISTRIBUTION OF NEW CANCER PATIENTS BY STAGE AND GENDER : 2023						
Staging	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	206	22.5	282	30.9	488	26.7
Stage II	196	21.5	199	21.8	395	21.6
Stage III	228	25.0	212	23.2	440	24.1
Stage IV	246	27.0	199	21.8	445	24.4
No stage	29	3.2	18	2.0	47	2.7
Unknown	7	0.8	3	0.3	10	0.5
Total	912	100.0	913	100.0	1825	100.0

*No stage: manual system including leukemia and brain

FIGURE 7: DISTRIBUTION OF NEW CANCER PATIENTS BY STAGE AND GENDER: 2023





HOSPITAL-BASED CANCER REGISTRY

2023

ANNUAL REPORT

TABLE 8 DISTRIBUTION OF NEW CANCER PATIENTS BY GRADE AND GENDER : 2023						
Grade	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Well differentiated	115	12.6	116	12.7	231	12.7
Moderately differentiated	204	22.4	210	23.0	414	22.7
Poorly differentiated	199	21.8	219	24.0	418	22.9
Undifferentiated	68	7.5	9	1.0	77	4.2
T – Cell	40	4.4	34	3.7	74	4.1
B – Cell	44	4.8	37	4.1	81	4.4
Differentiated not Determined	242	26.5	288	31.5	530	29.0
Total	912	100.0	913	100.0	1825	100.0

FIGURE 8: DISTRIBUTION OF NEW CANCER PATIENTS BY GRADE AND GENDER: 2023







TABLE 9		DISTRIBUTION OF NEW CANCER PATIENTS BY EXTENSION AND GENDER : 2023				
Extend	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	587	64.4	603	66.1	1190	65.2
Regional lymph nodes	138	15.1	137	15.0	275	15.1
Distant metastasis	187	20.5	173	18.9	360	19.7
Total	912	100.0	913	100.0	1825	100.0

FIGURE 9: DISTRIBUTION OF NEW CANCER PATIENTS BY EXTENSION AND GENDER: 2023





HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT

2023

TABLE 10 DISTRIBUTION OF NEW CANCER PATIENTS BY METHOD AND GENDER : 2023						
Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Radiology	10	1.1	5	0.5	15	0.8
Histopathology or Cytology	746	81.8	819	89.7	1565	85.8
Endoscopy	10	1.1	4	0.4	14	0.8
Bone marrow examination	83	9.1	69	7.6	152	8.3
Tumor marker	63	6.9	16	1.8	79	4.3
Total	912	100.0	913	100.0	1825	100.0

FIGURE 10: DISTRIBUTION OF NEW CANCER PATIENTS BY METHOD AND GENDER: 2023






TABLE 11.1 DISTRIBUTION OF NEW CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2023						
Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	284	31.2	314	34.4	598	32.7
Radiation	108	11.8	102	11.3	210	11.4
Chemotherapy	126	13.8	115	12.6	241	13.1
Hormone	1	0.1	1	0.1	2	0.1
Immunotherapy	10	1.1	17	1.9	27	1.4
Interventional	29	3.2	29	3.2	58	3.2
Surgery and Radiotherapy	38	4.2	25	2.7	63	3.4
Surgery and Chemotherapy	109	12.0	122	13.4	231	12.7
Surgery and Immunotherapy	2	0.2	4	0.4	6	0.3
Surgery and Interventional	1	0.1	0	0.0	1	0.1
Radiotherapy and Chemotherapy	12	1.3	20	2.2	32	1.8
Radiation and Hormone	1	0.1	0	0.0	1	0.1
Radiotherapy and Immunotherapy	1	0.1	3	0.3	4	0.2
Chemotherapy and Immunotherapy	21	2.3	36	3.9	57	3.1
Chemotherapy and Interventional	13	1.4	14	1.5	27	1.5
Surgery, Radiotherapy and Chemotherapy	17	1.9	8	0.9	25	1.4



TABLE 11.2 DISTRIBUTION OF NEW CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2023						
Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery, Radiotherapy and Hormone	1	0.1	0	0.0	1	0.1
Surgery, Radiotherapy and Immunotherapy	3	0.3	0	0.0	3	0.2
Surgery, Chemotherapy and Immunotherapy	14	1.5	5	0.5	19	1.0
Surgery, Chemotherapy and Interventional	1	0.1	2	0.2	3	0.2
Radiotherapy, Chemotherapy and Immunotherapy	0	0.0	1	0.1	1	0.1
Radiotherapy, Chemotherapy and Interventional	1	0.1	0	0.0	1	0.1
Radiotherapy, Hormone and Immunotherapy	1	0.1	0	0.0	1	0.1
Chemotherapy, Hormone and Immunotherapy	1	0.1	0	0.0	1	0.1
Surgery, Radiotherapy, Chemotherapy and Immunotherapy	1	0.1	0	0.0	1	0.1
Counseling	116	12.8	95	10.4	211	11.5
Total	912	100.0	913	100.0	1825	100.0



TABLE 12 DISTRIBUTION OF NEW CANCER PATIENTS BY TREATMENT UNIT AND GENDER : 2023						
Treatment unit	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Medicine oncology	396	43.4	240	26.3	636	34.9
Surgery oncology	380	41.7	330	36.1	710	38.9
Ear Nose and Throat oncology	81	8.8	62	6.8	143	7.8
Gynecologic oncology	0	0.0	145	15.9	145	7.9
Radiotherapy oncology	37	4.1	119	13.0	156	8.6
Pediatric oncology	10	1.1	10	1.1	20	1.1
Orthopedics oncology	8	0.9	7	0.8	15	0.8
Total	912	100.0	913	100.0	1825	100.0

FIGURE 11: DISTRIBUTION OF NEW CANCER PATIENTS BY TREATMENT UNIT AND GENDER: 2023






TABLE 13 DISTRIBUTION OF NEW CANCER PATIENTS BY STATUS : 2023						
Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Military	279	30.6	40	4.4	319	17.5
Civilian	633	69.4	873	95.6	1506	82.5
Total	912	100.0	913	100.0	1825	100.0

TABLE 14 DISTRIBUTION OF NEW CANCER PATIENTS BY FOLLOW UP STATUS AND GENDER : 2023						
Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	891	97.7	906	99.2	1797	98.5
Deaths	21	2.3	7	0.8	28	1.5
Total	912	100.0	913	100.0	1825	100.0

Survey: 30 June 2024

FIGURE 12: DISTRIBUTION OF NEW CANCER PATIENTS BY FOLLOW UP STATUS: 2023






TABLE 15

DISTRIBUTION OF NEW MILITARY PERSONNEL CANCER PATIENTS BY AGE GROUP AND GENDER : 2023

Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
0 – 24	3	1.1	0	0.0	3	0.9
25 – 29	4	1.4	2	5.0	6	1.9
30 – 34	5	1.8	2	5.0	7	2.2
35 – 39	4	1.4	2	5.0	6	1.9
40 – 44	5	1.8	3	7.5	8	2.4
45 – 49	10	3.6	3	7.5	13	4.1
50 – 54	12	4.3	7	17.5	19	6.0
55 – 59	22	7.9	4	10.0	26	8.2
60 – 64	47	16.8	6	15.0	53	16.6
65 – 69	51	18.3	4	10.0	55	17.1
70 – 74	46	16.5	3	7.5	49	15.4
75 – 79	41	14.7	1	2.5	42	13.2
80 – 84	10	3.6	3	7.5	13	4.1
85 +	19	6.8	0	0.0	19	6.0
Total	279	100.0	40	100.0	319	100.0

Majority of cases

FIGURE 13: DISTRIBUTION OF NEW MILITARY PERSONNEL CANCER PATIENTS BY AGE GROUP AND GENDER: 2023






TABLE 16 DISTRIBUTION OF NEW CANCER PATIENTS BY RANK AND GENDER : 2023						
Rank	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Major General – General	62	22.3	5	12.5	67	21.0
Major – Colonel	84	30.1	21	52.5	105	32.9
Sub Lieutenant – Captain	84	30.1	5	12.5	89	27.9
Sergeant Major 3 rd - Sergeant Major 1 st	36	12.9	4	10.0	40	12.6
Private 1 st class – Sergeant	11	3.9	5	12.5	16	5.0
Enlisted Soldier	2	0.7	0	0.0	2	0.6
Total	279	100.0	40	100.0	319	100.0

FIGURE 14: DISTRIBUTION OF NEW CANCER PATIENTS BY RANK AND GENDER: 2023






TABLE 17 DISTRIBUTION OF NEW CHILDHOOD CANCER PATIENTS (AGE 0 - 19) BY AGE GROUP AND GENDER : 2023						
Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
0 – 4	4	36.4	3	25.0	7	30.4
5 – 9	3	27.2	3	25.0	6	26.1
10 – 14	2	18.2	4	33.3	6	26.1
15 - 19	2	18.2	2	16.7	4	17.4
Total	11	100.0	12	100.0	23	100.0

TABLE 18 DISTRIBUTION OF NEW CHILDHOOD CANCER PATIENTS (AGE 0 - 19) BY PRIMARY SITES : 2023						
Ordinal	Primary site	Male		Female		Total
		Number		Number		Number Percent
1	leukemia	6		5		11 47.9
2	Brain	1		2		3 13.1
3	Non-Hodgkin's lymphoma	1		1		2 8.7
4	Thyroid gland	1		1		2 8.7
5	Adrenal gland	2		0		2 8.7
6	Bone and articular cartilage	0		1		1 4.3
7	Hodgkin's disease	0		1		1 4.3
8	Kidney, renal pelvis and ureter	0		1		1 4.3
Total		11		12		23 100.0



TABLE 19

DISTRIBUTION OF NEW CHILDHOOD CANCER PATIENTS (AGE 0 - 19)
BY TREATMENT MODALITIES AND GENDER : 2023

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	0	0.0	2	16.7	2	8.8
Radiation	0	0.0	3	25.0	3	13.0
Chemotherapy	7	63.6	6	50.0	13	56.5
Surgery and Radiotherapy	1	9.1	0	0.0	1	4.3
Radiotherapy and Chemotherapy	1	9.1	0	0.0	1	4.3
Surgery, Radiotherapy and Chemotherapy	1	9.1	1	8.3	2	8.8
Counseling	1	9.1	0	0.0	1	4.3
Total	11	100.0	12	100.0	23	100.0

TABLE 20

DISTRIBUTION OF NEW CHILDHOOD CANCER PATIENTS (AGE 0 - 19)
BY METHOD AND GENDER : 2023


Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Bone marrow	7	63.6	7	58.3	14	60.9
Histopathology or Cytology	4	36.4	5	41.7	9	39.1
Total	11	100.0	12	100.0	23	100.0



TABLE 21	DISTRIBUTION OF NEW CHILDHOOD CANCER PATIENTS (AGE 0 - 19) BY TYPE OF EXTENSION AND GENDER : 2023					
	Spreading/Metastasis	Male		Female		Total
		Number	Percent	Number	Percent	Number Percent
	Localized	11	100.0	11	91.7	22 95.7
	Regional lymph nodes	0	0.0	1	8.3	1 4.3
	Total	11	100.0	12	100.0	23 100.0

TABLE 22	DISTRIBUTION OF NEW CHILDHOOD CANCER PATIENTS (AGE 0 - 19) BY FOLLOW UP AND GENDER : 2023					
	Follow up status	Male		Female		Total
		Number	Percent	Number	Percent	Number Percent
	Alive	10	90.9	12	100.0	22 95.7
	Deaths	1	9.1	0	0.0	1 4.3
	Total	11	100.0	12	100.0	23 100.0

Survey: 30 June 2024





HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT

2023

TABLE 23	NUMBER OF NEW CANCER PATIENTS STAGE AND GENDER : 2023								
Site	Sex	Stage							
		I	II	III	IV	No stage	Un known	Total	
Adrenal gland	Male	-	-	-	-	2	-	2	
	Female	-	-	-	-	0	-	0	
	Total	(N)	-	-	-	-	2	-	2
		(%)	-	-	-	-	100.0	-	100.0
Anus and anus canal	Male	2	3	4	3	-	-	12	
	Female	0	3	3	1	-	-	7	
	Total	(N)	2	6	7	4	-	-	19
		(%)	100.0	100.0	100.0	100.0	-	-	100.0
Bladder	Male	12	9	8	5	-	-	34	
	Female	4	3	2	2	-	-	11	
	Total	(N)	16	12	10	7	-	-	45
		(%)	100.0	100.0	100.0	100.0	-	-	100.0
Bone and articular cartilage	Male	5	0	3	1	-	-	9	
	Female	3	3	2	0	-	-	8	
	Total	(N)	8	3	5	1	-	-	17
		(%)	100.0	100.0	100.0	100.0	-	-	100.0
Brain	Male	2	0	-	1	7	-	10	
	Female	0	1	-	0	6	-	7	
	Total	(N)	2	1	-	1	13	-	17
		(%)	100.0	100.0	-	100.0	100.0	-	100.0
Breast	Male	1	1	0	0	-	-	2	
	Female	46	70	50	21	-	-	187	
	Total	(N)	47	71	50	21	-	-	189
		(%)	100.0	100.0	100.0	100.0	-	-	100.0
Cervix	Male	0	0	0	0	-	-	0	
	Female	21	17	19	2	-	-	59	
	Total	(N)	21	17	19	2	-	-	59
		(%)	100.0	100.0	100.0	100.0	-	-	100.0



TABLE 23	NUMBER OF NEW CANCER PATIENTS STAGE AND GENDER : 2023								
Site	Sex	Stage							Total
		I	II	III	IV	No stage	Un known		
Colon and Rectum	Male		18	43	36	50	-	-	147
	Female		11	30	31	30	-	-	102
	Total	(N)	29	73	67	80	-	-	249
		(%)	100.0	100.0	100.0	100.0	-	-	100.0
Uterus	Male		0	0	0	0	-	-	0
	Female		25	5	14	7	-	-	51
	Total	(N)	25	5	14	7	-	-	51
		(%)	100.0	100.0	100.0	100.0	-	-	100.0
Female genital organs	Male		0	0	0	0	-	-	0
	Female		2	1	3	1	-	-	7
	Total	(N)	2	1	3	1	-	-	7.0
		(%)	100.0	100.0	100.0	100.0	-	-	100.0
Gall bladder and unspecified parts of biliary tract	Male		3	2	4	4	-	-	13
	Female		4	2	0	7	-	-	13
	Total	(N)	7	4	4	11	-	-	26.0
		(%)	100.0	100.0	100.0	100.0	-	-	100.0
Hodgkin's disease	Male		-	2	0	-	-	-	2
	Female		-	0	1	-	-	-	1
	Total	(N)	-	2	1	-	-	-	3
		(%)	-	100.0	100.0	-	-	-	100.0
Hypopharynx	Male		1	1	1	5	-	-	8
	Female		0	0	0	0	-	-	0
	Total	(N)	1	1	1	5	-	-	8
		(%)	100.0	100.0	100.0	100.0	-	-	100.0
Intrathoracic organs	Male		-	0	1	1	-	-	2
	Female		-	1	2	1	-	-	4
	Total	(N)	-	1	3	2	-	-	6
		(%)	-	-	-	-	-	-	100.0



TABLE 23

NUMBER OF NEW CANCER PATIENTS STAGE AND GENDER : 2023

Site	Sex	Stage						
		I	II	III	IV	No stage	Un known	Total
Kidney, renal pelvis & ureter	Male	7	4	6	5	-	-	22
	Female	8	3	4	5	-	-	20
	Total	(N) 15	7	10	10	-	-	
		(%) 100.0	100.0	100.0	100.0	-	-	100.0
Larynx	Male	4	-	2	5	-	-	11
	Female	0	-	0	0	-	-	0
	Total	(N) 4	-	2	5	-	-	11
		(%) 100.0	-	100.0	100.0	-	-	100.0
Leukemia	Male	2	3	1	4	20	-	30
	Female	4	2	0	1	12	-	19
	Total	(N) 6	5	1	5	32	-	49
		(%) 100.0	100.0	100.0	100.0	100.0	-	100.0
Lip and Oral cavity	Male	2	6	3	9	-	-	20
	Female	3	2	4	3	-	-	12
	Total	(N) 5	8	7	12	-	-	32
		(%) 100.0	100.0	100.0	100.0	-	-	100.0
Mesothelial and soft tissue	Male	3	3	7	3	-	1	17
	Female	5	3	2	3	-	0	13
	Total	(N) 8	6	9	6	-	1	30
		(%) 100.0	100.0	100.0	100.0	-	100.0	100.0
multiple myeloma	Male	6	2	7	0	-	1	16
	Female	4	4	4	3	-	0	15
	Total	(N) 10	6	11	3	-	1	31
		(%) 100.0	100.0	100.0	100.0	-	100.0	100.0
Nasal cavity and accessory issues	Male	3	0	2	2	-	-	7
	Female	1	1	0	1	-	-	3
	Total	(N) 4	1	2	3	-	-	10
		(%) 100.0	100.0	100.0	100.0	-	-	100.0

2023 HOSPITAL-BASED CANCER REGISTRY ANNUAL REPORT



TABLE 23	NUMBER OF NEW CANCER PATIENTS STAGE AND GENDER : 2023								
Site	Sex	Stage							Total
		I	II	III	IV	No stage	Un known		
Nasopharynx	Male	-	1	8	4	-	-	13	
	Female	-	0	3	2	-	-	5	
	Total	(N)	1	11	6	-	-	18	
		(%)	-	100.0	100.0	100.0	-	-	100.0
Non-Hodgkin's lymphoma	Male	7	6	13	12	-	0	38	
	Female	8	3	13	11	-	1	36	
	Total	(N)	15	9	26	23	-	1	74
		(%)	100.0	100.0	100.0	100.0	-	100.0	100.0
Esophagus	Male	1	1	10	4	-	-	16	
	Female	0	0	0	0	-	-	0	
	Total	(N)	1	1	10	4	-	-	16
		(%)	100	100.0	100.0	100.0	-	-	100.0
Oropharynx	Male	2	3	3	3	-	1	12	
	Female	0	1	0	0	-	0	1	
	Total	(N)	2	4	3	3	-	1	13
		(%)	100.0	100.0	100.0	100.0	-	100.0	100.0
Other endocrine glands and relate structures	Male	0	-	-	1	-	-	1	
	Female	2	-	-	3	-	-	5	
	Total	(N)	2	-	-	4	-	-	6
		(%)	100.0	-	-	100.0	-	-	100.0
Ovary	Male	0	0	0	0	-	-	0	
	Female	12	7	9	5	-	-	33	
	Total	(N)	12	7	9	5	-	-	33
		(%)	100.0	100.0	100.0	100.0	-	-	100.0
Pancreas	Male	5	2	6	9	-	-	22	
	Female	2	1	4	11	-	-	18	
	Total	(N)	7	3	10	20	-	-	40
		(%)	100.0	100.0	100.0	100.0	-	-	100.0



TABLE 23

NUMBER OF NEW CANCER PATIENTS STAGE AND GENDER : 2023

Site	Sex	Stage							
		I	II	III	IV	No stage	Un known	Total	
Prostate gland	Male		48	43	22	29	-	4	146
	Female		0	0	0	0	-	0	0
	Total	(N)	48	43	22	29	-	4	146
		(%)	100.0	100.0	100.0	100.0	-	100.0	100.0
Pyriform sinus	Male		-	-	1	1	-	-	2
	Female		-	-	0	0	-	-	0
	Total	(N)	-	-	1	1	-	-	2
		(%)	-	-	100.0	100.0	-	-	100.0
Liver and intrahepatic bile ducts	Male		16	41	24	17	-	-	98
	Female		5	9	8	6	-	-	28
	Total	(N)	21	50	32	23	-	-	126
		(%)	100.0	100.0	100.0	100.0	-	-	100.0
Skin	Male		16	4	3	1	-	-	24
	Female		13	3	5	1	-	-	22
	Total	(N)	29	7	8	2	-	-	46
		(%)	100.0	100.0	100.0	100.0	-	-	100.0
Small intestine	Male		1	-	0	0	-	-	1
	Female		0	-	1	2	-	-	3
	Total	(N)	1	-	1	2	-	-	4
		(%)	100.0	-	100.0	100.0	-	-	100.0
Stomach	Male		0	3	9	1	-	0	13
	Female		1	3	5	4	-	1	14
	Total	(N)	1	6	14	5	-	1	27
		(%)	100.0	100.0	100.0	100.0	-	100.0	100.0
Thyroid gland	Male		22	4	6	1	-	-	33
	Female		84	17	11	6	-	-	118
	Total	(N)	106	21	17	7	-	-	151
		(%)	100.0	100.0	100.0	100.0	-	-	100.0

2023 HOSPITAL-BASED CANCER REGISTRY ANNUAL REPORT




TABLE 23	NUMBER OF NEW CANCER PATIENTS STAGE AND GENDER : 2023								
Site	Sex	Stage						Total	
		I	II	III	IV	No stage	Un known		
Tonsil	Male		1	1	3	2	-	-	7
	Female		0	0	1	0	-	-	1
	Total	(N)	1	1	4	2	-	-	8
		(%)	100.0	100.0	100.0	100.0	-	-	100.0
Trachea, bronchus and lung	Male		11	7	30	60	-	0	108
	Female		14	4	11	58	-	1	88
	Total	(N)	25	11	41	118	-	1	196
		(%)	100.0	100.0	100.0	100.0	-	100.0	100.0
Without specification of site	Male		-	-	2	0	-	-	2
	Female		-	-	0	2	-	-	2
	Total	(N)	-	-	2	2	-	-	4
		(%)	-	-	100.0	100.0	-	-	100.0
Male genital organs	Male		5	1	3	2	-	-	11
	Female		0	0	0	0	-	-	0
	Total	(N)	5	1	3	2	-	-	11
		(%)	100.0	100.0	100.0	100.0	-	-	100.0
Total	Male		206	196	228	246	29	7	912
	Female		282	199	212	199	18	3	913
	Total	(N)	488	395	440	445	47	10	1825
		(%)	100.0	100.0	100.0	100.0	100.0	100.0	100.0



**DESCRIPTION OF THE LEADING
SITES OF CANCERS**

.....

1. Colon and Rectum
2. Trachea, bronchus and lung
3. Breast
4. Thyroid gland
5. Prostate gland
6. Liver and intrahepatic bile ducts





1
COLON AND RECTUM
CANCER




TABLE 24

TREND OF COLON AND RECTUM CANCER IN PHRAMONGKUTKLAO HOSPITAL :
2012 - 2023

Years	Number of patients		Total
	Male	Female	
2012	146	78	224
2013	131	87	218
2014	130	87	217
2015	120	81	201
2016	140	88	228
2017	102	67	169
2018	104	56	160
2019	132	91	223
2020	107	72	179
2021	117	82	199
2022	140	95	235
2023	147	102	249



COLON AND RECTUM CANCER


TABLE 25

DISTRIBUTION OF COLON AND RECTUM CANCER PATIENTS BY AGE GROUP AND GENDER : 2023

Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 – 29	0	0.0	1	1.0	1	0.4
30 – 34	1	0.7	1	1.0	2	0.8
35 – 39	1	0.7	5	4.8	6	2.5
40 – 44	4	2.7	6	5.9	10	4.0
45 – 49	9	6.2	5	4.8	14	5.6
50 – 54	15	10.2	12	11.8	27	10.8
55 – 59	16	10.9	12	11.8	28	11.2
60 – 64	20	13.6	12	11.8	32	12.9
65 – 69	26	17.7	11	10.8	37	14.9
70 – 74	25	17.0	10	9.8	35	14.1
75 – 79	13	8.8	11	10.8	24	9.6
80 – 84	8	5.4	10	9.8	18	7.2
85 +	9	6.1	6	5.9	15	6.0
Total	147	100.0	102	100.0	249	100.0

Majority of cases

FIGURE 15: DISTRIBUTION OF COLON & RECTUM CANCER PATIENTS BY AGE GROUP AND GENDER: 2023






COLON AND RECTUM CANCER

Staging	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	18	12.2	11	10.8	29	11.6
Stage II	43	29.3	30	29.4	73	29.3
Stage III	36	24.5	31	30.4	67	26.9
Stage IV	50	34.0	30	29.4	80	32.2
Total	147	100.0	102	100.0	249	100.0

FIGURE 16: DISTRIBUTION OF NEW COLON & RECTUM CANCER PATIENTS BY STAGE AND GENDER: 2023





COLON AND RECTUM CANCER

TABLE 27

DISTRIBUTION OF NEW COLON AND RECTUM CANCER PATIENTS BY METHOD AND GENDER : 2023


Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Radiology	1	0.7	0	0.0	1	0.4
Histopathology or Cytology	138	93.9	98	96.1	236	94.8
Endoscopy	8	5.4	4	3.9	12	4.8
Total	147	100.0	102	100.0	249	100.0

TABLE 28

DISTRIBUTION OF NEW COLON AND RECTUM CANCER PATIENTS BY EXTENSION AND GENDER : 2023

Extension	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	67	45.6	53	52.0	120	48.2
Regional lymph nodes	33	22.4	21	20.6	54	21.7
Distant metastasis	47	32.0	28	27.5	75	30.1
Total	147	100.0	102	100.0	249	100.0

FIGURE 17: DISTRIBUTION OF NEW COLON & RECTUM CANCER PATIENTS BY EXTENSION AND GENDER: 2023





COLON AND RECTUM CANCER

TABLE 29	DISTRIBUTION OF NEW COLON & RECTUM CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2023					
	Treatment modality	Male		Female		Total
		Number	Percent	Number	Percent	Number Percent
	Surgery	48	32.6	40	39.2	88 35.3
	Radiation	10	6.8	5	4.9	15 6.0
	Chemotherapy	10	6.8	14	13.7	24 9.7
	Surgery and Radiotherapy	0	0.0	1	1.0	1 0.4
	Surgery and Chemotherapy	55	37.3	32	31.3	87 34.9
	Surgery and Immunotherapy	1	0.7	0	0.0	1 0.4
	Radiotherapy and Chemotherapy	2	1.4	2	2.0	4 1.7
	Chemotherapy and Immunotherapy	2	1.4	1	1.0	3 1.2
	Surgery, Radiotherapy and Chemotherapy	2	1.4	0	0.0	2 0.8
	Surgery, Radiotherapy and Hormone	1	0.7	0	0.0	1 0.4
	Surgery, Chemotherapy and Immunotherapy	1	0.7	0	0.0	1 0.4
	Counseling	15	10.2	7	6.9	22 8.8
	Total	147	100.0	102	100.0	249 100.0

TABLE 30	DISTRIBUTION OF NEW COLON & RECTUM CANCER PATIENTS BY TREATMENT FOLLOW UP STATUS AND GENDER : 2023					
	Follow up status	Male		Female		Total
		Number	Percent	Number	Percent	Number Percent
	Alive	145	98.6	102	100.0	247 99.2
	Deaths	2	1.4	0	0.0	2 0.8
	Total	147	100.0	102	100.0	249 100.0



2

TRACHEA, BRONCHUS
AND LUNG
CANCER




TABLE 31

TREND OF TRACHEA, BRONCHUS AND LUNG CANCER IN PHRAMONGKUTKLAO HOSPITAL : 2012 - 2023

Years	Number of patients		Total
	Male	Female	
2012	146	78	224
2013	131	87	218
2014	130	87	217
2015	120	81	201
2016	140	88	228
2017	102	67	169
2018	104	56	160
2019	132	91	223
2020	107	72	179
2021	117	82	199
2022	111	97	208
2023	108	88	196



TRACHEA, BRONCHUS AND LUNG CANCER


TABLE 32

DISTRIBUTION OF TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY AGE GROUP AND GENDER : 2023

Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 – 29	0	0.0	1	1.1	1	0.5
30 – 34	1	0.9	2	2.4	3	1.6
35 – 39	0	0.0	1	1.1	1	0.5
40 – 44	0	0.0	1	1.1	1	0.5
45 – 49	13	12.0	10	11.4	23	11.7
50 – 54	10	9.3	7	8.0	17	8.8
55 – 59	13	12.0	11	12.5	24	12.2
60 – 64	24	22.2	6	6.8	30	15.3
65 – 69	11	10.2	21	23.9	32	16.3
70 – 74	22	20.4	9	10.2	31	15.8
75 – 79	9	8.3	4	4.5	13	6.6
80 – 84	2	1.9	9	10.2	11	5.6
85 +	3	2.8	6	6.8	9	4.6
Total	108	100.0	88	100.0	196	100.0

Majority of cases

FIGURE 18: DISTRIBUTION OF TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY AGE GROUP AND GENDER: 2023






TRACHEA, BRONCHUS AND LUNG CANCER

TABLE 33

DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY STAGE AND GENDER : 2023

Staging	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	11	10.2	14	15.9	25	12.8
Stage II	7	6.4	4	4.5	11	5.6
Stage III	30	27.8	11	12.5	41	20.9
Stage IV	60	55.6	58	65.9	118	60.2
Unknown	0	0.0	1	1.2	1	0.5
Total	108	100.0	88	100.0	196	100.0

FIGURE 19: DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY STAGE ANDGENDER: 2023





TRACHEA, BRONCHUS AND LUNG CANCER

TABLE 34

DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY METHOD AND GENDER : 2023


Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Radiology	1	0.9	1	1.1	2	1.0
Histopathology or Cytology	107	99.1	87	98.9	194	99.0
Total	108	100.0	88	100.0	196	100.0

TABLE 35

DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY EXTENSION AND GENDER : 2023

Extension	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	29	26.9	23	26.1	52	26.5
Regional lymph nodes	24	22.2	10	11.4	34	17.3
Distant metastasis	55	50.9	55	62.5	110	56.2
Total	108	100.0	88	100.0	196	100.0

FIGURE 20: DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY EXTENSION AND GENDER: 2023





TRACHEA, BRONCHUS AND LUNG CANCER

TABLE 36**DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2023**

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	38	35.2	37	42.0	75	38.3
Radiation	5	4.6	4	4.5	9	4.6
Chemotherapy	15	13.9	13	14.8	28	14.3
Surgery and Radiotherapy	1	0.9	1	1.1	2	1.0
Surgery and Chemotherapy	6	5.6	7	8.0	13	6.6
Surgery and Immunotherapy	0	0.0	1	1.1	1	0.5
Radiotherapy and Chemotherapy	5	4.6	3	3.4	8	4.1
Chemotherapy and Immunotherapy	9	8.2	0	0.0	9	4.6
Surgery, Radiotherapy and Immunotherapy	0	0.0	2	2.3	2	1.0
Surgery, Chemotherapy and Immunotherapy	2	1.9	0	0.0	2	1.0
Radiotherapy, Chemotherapy and Immunotherapy	1	0.9	0	0.0	1	0.5
Radiotherapy, Hormone and Immunotherapy	0	0.0	1	1.1	1	0.5
Counseling	26	24.2	19	21.7	45	23.0
Total	108	100.0	88	100.0	196	100.0

TABLE 37**DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY TREATMENT FOLLOW UP STATUS AND GENDER : 2023**

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	102	94.4	88	100.0	190	96.9
Deaths	6	5.6	0	0.0	6	3.1
Total	108	100.0	88	100.0	196	100.0

Survey: 30 June 2024



3
BREAST
CANCER




TABLE 38 TREND OF BREAST CANCER IN PHRAMONGKUTKLAO HOSPITAL : 2012 - 2023

Years	Number of patients		Total
	Male	Female	
2012	1	291	292
2013	1	285	286
2014	0	261	261
2015	2	197	199
2016	2	198	200
2017	5	166	171
2018	4	180	184
2019	3	206	209
2020	3	181	184
2021	2	210	212
2022	5	221	226
2023	2	187	189




BREAST CANCER

TABLE 39 DISTRIBUTION OF BREAST CANCER PATIENTS BY AGE GROUP AND GENDER : 2023

Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 – 24	0	0.0	2	1.1	2	1.1
25 – 29	0	0.0	1	0.5	1	0.5
30 – 34	0	0.0	2	1.1	2	1.1
35 – 39	0	0.0	12	6.4	12	6.3
40 – 44	0	0.0	18	9.6	18	9.5
45 – 49	0	0.0	29	15.5	29	15.3
50 – 54	0	0.0	23	12.3	23	12.2
55 – 59	0	0.0	25	13.4	25	13.2
60 – 64	0	0.0	23	12.3	23	12.2
65 – 69	1	50.0	22	11.8	23	12.2
70 – 74	0	0.0	15	8.0	15	7.9
75 – 79	0	0.0	6	3.2	6	3.2
80 – 84	1	50.0	7	3.7	8	4.2
85 +	0	0.0	2	1.1	2	1.1
Total	2	100.0	187	100.0	189	100.0

Majority of cases

FIGURE 21: DISTRIBUTION OF BREAST CANCER PATIENTS BY AGE GROUP AND GENDER: 2023






BREAST CANCER

TABLE 40 DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY STAGE AND GENDER : 2023						
Staging	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	1	50.0	46	24.6	47	24.9
Stage II	1	50.0	70	37.5	71	37.6
Stage III	0	0.0	50	26.7	50	26.5
Stage IV	0	0.0	21	11.2	21	11.0
Total	2	100.0	187	100.0	189	100.0

FIGURE 22: DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY STAGE ANDGENDER: 2023






BREAST CANCER

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Radiology	0	0.0	1	0.5	1	0.5
Histopathology or Cytology	2	100.0	186	99.5	188	99.5
Total	2	100.0	187	100.0	189	100.0

Extension	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	2	100.0	112	59.9	114	60.3
Regional lymph nodes	0	0.0	54	28.9	54	28.6
Distant metastasis	0	0.0	21	11.2	21	11.1
Total	2	100.0	187	100.0	189	100.0

FIGURE 23: DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY EXTENSION AND GENDER: 2023





BREAST CANCER

TABLE 43 DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2023

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	2	100.0	24	12.8	26	13.8
Radiation	0	0.0	39	20.9	39	20.7
Chemotherapy	0	0.0	24	12.8	24	12.7
Hormone	0	0.0	2	1.1	2	1.1
Immunotherapy	0	0.0	3	1.6	3	1.6
Surgery and Radiotherapy	0	0.0	1	0.5	1	0.5
Surgery and Chemotherapy	0	0.0	51	27.4	51	27.0
Radiotherapy and Chemotherapy	0	0.0	1	0.5	1	0.5
Radiation and Hormone	0	0.0	1	0.5	1	0.5
Chemotherapy and Immunotherapy	0	0.0	14	7.5	14	7.4
Surgery, Radiotherapy and Chemotherapy	0	0.0	3	1.6	3	1.6
Surgery, Radiotherapy and Immunotherapy	0	0.0	1	0.5	1	0.5
Surgery, Chemotherapy and Immunotherapy	0	0.0	9	4.8	9	4.8
Chemotherapy, Hormone and Immunotherapy	0	0.0	1	0.5	1	0.5
Surgery, Radiotherapy, Chemotherapy and Immunotherapy	0	0.0	1	0.5	1	0.5
Counseling	0	0.0	12	6.5	12	6.3
Total	2	100.0	187	100.0	189	100.0

TABLE 44 DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY TREATMENT FOLLOW UP STATUS AND GENDER : 2023

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	2	100.0	187	100.0	189	100.0
Deaths	0	0.0	0	0.0	0	0.0
Total	2	100.0	187	100.0	189	100.0

Survey: 30 June 2024



4

THYROID GLAND
CANCER





TABLE 45

DISTRIBUTION OF THYROID GLAND CANCER PATIENTS BY AGE GROUP AND GENDER : 2023

Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 – 19	1	3.0	1	0.8	2	1.3
20 – 24	0	0.0	5	4.2	5	3.3
25 – 29	3	9.1	11	9.3	14	9.3
30 – 34	5	15.2	12	10.2	17	11.3
35 – 39	4	12.1	8	6.8	12	7.9
40 – 44	3	9.1	20	16.9	23	15.2
45 – 49	2	6.1	10	8.5	12	7.9
50 – 54	4	12.1	16	13.6	20	13.2
55 – 59	3	9.1	13	11.0	16	10.6
60 – 64	3	9.1	4	3.4	7	4.6
65 – 69	3	9.1	6	5.1	9	6.1
70 – 74	0	0.0	8	6.8	8	5.3
75 – 79	0	0.0	2	1.7	2	1.3
80 – 84	1	3.0	2	1.7	3	2.0
85 +	1	3.0	0	0.0	1	0.7
Total	33	100.0	118	100.0	151	100.0

Majority of cases

FIGURE 24: DISTRIBUTION OF THYROID GLAND CANCER PATIENTS BY AGE GROUP ANDGENDER: 2023






THYROID GLAND CANCER

TABLE 46 DISTRIBUTION OF NEW THYROID GLAND CANCER PATIENTS BY STAGE AND GENDER : 2023						
Staging	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	22	66.7	84	71.2	106	70.2
Stage II	4	12.1	17	14.4	21	13.9
Stage III	6	18.2	11	9.3	17	11.3
Stage IV	1	3.0	6	5.1	7	4.6
Total	33	100.0	118	100.0	151	100.0

FIGURE 25: DISTRIBUTION OF NEW THYROID GLAND CANCER PATIENTS BY STAGE ANDGENDER: 2023





THYROID GLAND CANCER

TABLE 47

DISTRIBUTION OF NEW THYROID GLAND CANCER PATIENTS BY METHOD AND GENDER : 2023


Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Histopathology or Cytology	33	100.0	118	100.0	151	100.0
Total	33	100.0	118	100.0	151	100.0

TABLE 48

DISTRIBUTION OF NEW THYROID GLAND CANCER PATIENTS BY EXTENSION AND GENDER : 2023

Extension	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	27	81.8	103	87.3	130	86.1
Regional lymph nodes	4	12.1	11	9.3	15	9.9
Distant metastasis	2	6.1	4	3.4	6	4.0
Total	33	100.0	118	100.0	151	100.0

FIGURE 26: DISTRIBUTION OF NEW THYROID GLAND CANCER PATIENTS BY EXTENSION AND GENDER: 2023





THYROID GLAND CANCER


TABLE 49 DISTRIBUTION OF NEW THYROID GLAND CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2023

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	12	36.4	16	13.6	28	18.4
Radiation	11	33.3	71	60.2	82	54.3
Chemotherapy	0	0.0	1	0.8	1	0.7
Surgery and Radiotherapy	9	27.3	23	19.5	32	21.2
Radiation and Chemotherapy	0	0.0	1	0.8	1	0.7
Surgery, Radiotherapy and Chemotherapy	0	0.0	1	0.8	1	0.7
Counseling	1	3.0	5	4.3	6	4.0
Total	33	100.0	118	100.0	151	100.0


TABLE 50 DISTRIBUTION OF NEW THYROID GLAND CANCER PATIENTS BY TREATMENT FOLLOW UP STATUS AND GENDER : 2023

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	33	100.0	117	99.2	150	99.3
Deaths	0	0.0	1	0.8	1	0.7
Total	33	100.0	118	100.0	151	100.0

Survey: 30 June 2024



PROSTATE GLAND CANCER




DISTRIBUTION OF PROSTATE GLAND CANCER PATIENTS BY AGE GROUP AND GENDER : 2023

Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 – 49	0	0.0	0	0.0	0	0.0
50 – 54	2	1.5	0	0.0	2	1.5
55 – 59	6	4.1	0	0.0	6	4.1
60 – 64	20	13.7	0	0.0	20	13.7
65 – 69	33	22.6	0	0.0	33	22.6
70 – 74	37	25.3	0	0.0	37	25.3
75 – 79	27	18.5	0	0.0	27	18.5
80 – 84	10	6.8	0	0.0	10	6.8
85 +	11	7.5	0	0.0	11	7.5
Total	146	100.0	0	0.0	146	100.0

Majority of cases

FIGURE 27: DISTRIBUTION OF PROSTATE GLAND CANCER PATIENTS BY AGE GROUP AND GENDER:
2023






PROSTATE GLAND CANCER

TABLE 52 DISTRIBUTION OF NEW PROSTATE GLAND CANCER PATIENTS BY STAGE AND GENDER : 2023						
Staging	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	48	32.9	0	0.0	48	32.9
Stage II	43	29.5	0	0.0	43	29.5
Stage III	22	15.1	0	0.0	22	15.1
Stage IV	29	19.9	0	0.0	29	19.9
Unknown	4	2.6	0	0.0	4	2.6
Total	146	100.0	0	0.0	146	100.0

FIGURE 28: DISTRIBUTION OF NEW PROSTATE GLAND CANCER PATIENTS BY STAGE ANDGENDER: 2023






PROSTATE GLAND CANCER

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Radiology	1	0.7	0	0.0	1	0.7
Histopathology or Cytology	145	99.3	0	0.0	145	99.3
Total	146	100.0	0	0.0	146	100.0

Extension	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	117	80.1	0	0.0	117	80.1
Regional lymph nodes	7	4.8	0	0.0	7	4.8
Distant metastasis	22	15.1	0	0.0	22	15.1
Total	146	100.0	0	0.0	146	100.0

FIGURE 29: DISTRIBUTION OF NEW PROSTATE GLAND CANCER PATIENTS BY EXTENSION AND GENDER: 2023





PROSTATE GLAND CANCER

TABLE 55 DISTRIBUTION OF NEW THYROID GLAND CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2023

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	62	42.5	0	0.0	62	42.5
Radiation	34	23.3	0	0.0	34	23.3
Chemotherapy	5	3.4	0	0.0	5	3.4
Surgery and Radiotherapy	6	4.0	0	0.0	6	4.0
Surgery and Chemotherapy	3	2.1	0	0.0	3	2.1
Surgery, Radiotherapy and Chemotherapy	1	0.7	0	0.0	1	0.7
Surgery, Chemotherapy and Immunotherapy	1	0.7	0	0.0	1	0.7
Counseling	34	23.3	0	0.0	34	23.3
Total	146	100.0	0	0.0	146	100.0

TABLE 56 DISTRIBUTION OF NEW THYROID GLAND CANCER PATIENTS BY TREATMENT FOLLOW UP STATUS AND GENDER : 2023

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	144	98.6	0	0.0	144	98.6
Deaths	2	1.4	0	0.0	2	1.4
Total	146	100.0	0	0.0	146	100.0

Survey: 30 June 2024





6

LIVER AND INTRAHEPATIC BILE DUCTS
CANCER





TABLE 57

DISTRIBUTION OF LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY AGE GROUP AND GENDER : 2023

Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 – 19	0	0.0	0	0.0	0	0.0
20 – 24	1	1.0	0	0.0	1	0.8
25 – 29	0	0.0	0	0.0	0	0.0
30 – 34	0	0.0	0	0.0	0	0.0
35 – 39	1	1.0	2	7.1	3	2.4
40 – 44	5	5.1	1	3.6	6	4.8
45 – 49	10	10.2	1	3.6	11	8.7
50 – 54	12	12.2	3	10.7	15	11.9
55 – 59	16	16.3	3	10.7	19	15.1
60 – 64	12	12.2	3	10.7	15	11.9
65 – 69	19	19.4	2	7.1	21	16.7
70 – 74	5	5.1	3	10.7	8	6.3
75 – 79	9	9.2	3	10.7	12	9.5
80 – 84	5	5.1	6	21.5	11	8.7
85 +	3	3.2	1	3.6	4	3.2
Total	98	100.0	28	100.0	126	100.0

Majority of cases

FIGURE 30: DISTRIBUTION OF LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY AGE GROUP ANDGENDER: 2023






LIVER AND INTRAHEPATIC BILE DUCTS CANCER

TABLE 58 DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY STAGE AND GENDER : 2023						
Staging	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	16	16.3	5	17.9	21	16.7
Stage II	41	41.9	9	32.1	50	39.6
Stage III	24	24.5	8	28.6	32	25.4
Stage IV	17	17.3	6	21.4	23	18.3
Total	98	100.0	28	100.0	126	100.0

FIGURE 31: DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY STAGE AND GENDER:2023





LIVER AND INTRAHEPATIC BILE DUCTS CANCER

TABLE 59

DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY METHOD AND GENDER : 2023


Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Radiology	2	2.0	0	0.0	2	1.6
Histopathology or Cytology	33	33.7	12	42.9	45	35.7
Tumor maker	63	64.3	16	57.1	79	62.7
Total	98	100.0	28	100.0	126	100.0

TABLE 60

DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY EXTENSION AND GENDER : 2023

Extension	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	80	81.6	23	82.1	103	81.7
Regional lymph nodes	3	3.1	0	0.0	3	2.4
Distant metastasis	15	15.3	5	17.9	20	15.9
Total	98	100.0	28	100.0	126	100.0

FIGURE 32: DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY EXTENSION AND GENDER: 2023





LIVER AND INTRAHEPATIC BILE DUCTS CANCER

TABLE 61 DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2023

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	19	19.4	8	28.6	27	21.4
Radiation	1	1.0	0	0.0	1	0.8
Chemotherapy	14	14.3	0	0.0	14	11.1
Interventional	34	34.7	10	35.6	44	34.9
Surgery and Radiotherapy	1	1.0	1	3.6	2	1.6
Surgery and Chemotherapy	5	5.1	0	0.0	5	4.0
Surgery and Interventional	1	1.0	0	0.0	1	0.8
Chemotherapy and Immunotherapy	1	1.0	1	3.6	2	1.6
Chemotherapy and Interventional	19	19.4	6	21.4	25	19.8
Surgery, Chemotherapy and Immunotherapy	0	0.0	1	3.6	1	0.8
Surgery, Chemotherapy and Interventional	3	3.1	0	0.0	3	2.4
Radiotherapy, Chemotherapy and Interventional	0	0.0	1	3.6	1	0.8
Counseling	0	0.0	0	0.0	0	0.0
Total	98	100.0	28	100.0	126	100.0

TABLE 62 DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY TREATMENT FOLLOW UP STATUS AND GENDER : 2023

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	95	96.9	28	100.0	123	97.6
Deaths	3	3.1	0	0.0	3	2.4
Total	98	100.0	28	100.0	126	100.0

Survey: 30 June 2024



● MALE ●

TABLE 63		DISTRIBUTION OF NEW CANCER IN MALE BY AGE - GROUP : 2023																		
ICD_10	Site	Age	0	5	10	15	20	25	30	35	40	45	50	55	60	65	70	75	80	85
			-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
		Total	4	9	14	19	24	29	34	39	44	49	54	59	64	69	74	79	84	
C00-C08	Lip & Oral cavity	20	0	0	0	0	0	0	0	1	1	2	3	3	3	3	2	2	0	0
C01,C05,C10	Oropharynx	12	0	0	0	0	0	0	0	1	2	2	1	0	1	3	0	1	0	1
C09	Tonsil	7	0	0	0	0	0	0	0	0	2	0	0	1	2	1	0	1	0	0
C11	Nasopharynx	13	0	0	0	0	1	0	0	2	1	3	0	4	2	0	0	0	0	0
C13	Hypopharynx	8	0	0	0	0	0	0	0	0	0	0	2	1	1	1	2	1	0	0
C12	Pyriform sinus	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0
C15	Esophagus	16	0	0	0	0	0	0	0	0	1	3	1	1	4	3	0	1	2	0
C16	Stomach	14	0	0	0	0	1	0	1	0	2	0	0	4	1	1	1	1	1	1
C17	Small intestine	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
C18-C20	Colon and Rectum	147	0	0	0	0	0	0	1	1	4	9	15	16	20	26	25	13	8	9
C21	Anus	12	0	0	0	0	0	0	0	1	1	2	0	4	1	1	0	2	0	0
C22	Liver and Bile ducts	98	0	0	0	0	1	0	0	1	5	10	12	16	12	19	5	9	5	3
C23-C24	Gallbladder	13	0	0	0	0	0	0	0	0	0	1	3	3	0	1	1	2	1	1
C25	Pancreas	22	0	0	0	0	1	0	1	0	2	1	1	3	6	1	4	1	0	1
C30-C31	Nose, sinuses etc	7	0	0	0	0	0	1	0	2	0	0	0	0	3	1	0	0	0	0
C32	Larynx	11	0	0	0	0	0	0	0	0	1	0	3	3	0	3	0	1	0	0
C33-C34	Trachea, bronchus, lung	108	0	0	0	0	0	0	1	0	0	13	10	13	24	11	22	9	2	3
C37-C39	Other thoracic organs	2	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0
C40-C41	Bone & joints	9	0	0	0	0	1	1	1	0	0	1	0	1	1	2	1	0	0	0
C43-C44	Skin	24	0	0	0	0	0	0	1	0	0	1	2	1	2	3	3	3	3	5
C45-C49	Mesothelioma	17	0	0	0	0	1	1	2	2	0	1	1	3	3	1	1	0	0	1
C50	Breast	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0
C60, C62-C63	Male genital organs	11	0	0	0	0	5	1	0	0	1	0	1	1	0	0	0	1	0	1
C61	Prostate	146	0	0	0	0	0	0	0	0	0	0	2	6	20	33	37	27	10	11
C64-C66	Kidney & Ureter	22	0	0	0	0	2	1	0	0	0	2	3	3	5	2	1	2	1	0
C67	Bladder	34	0	0	0	0	0	0	0	0	0	2	0	1	2	7	5	4	7	6
C71-C72	Brain	10	0	0	1	0	1	2	1	1	1	0	0	1	0	1	0	1	0	0
C73	Thyroid gland	33	0	0	0	1	0	3	5	4	3	2	4	3	3	3	0	0	1	1
C74	Adrenal gland	2	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C75-C79	Other endocrine glands	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
C80	Without unspecified	2	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0
C81	Hodgkin's disease	2	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0
C82 -C85,	Non-Hodgkin lymphoma	38	1	0	0	0	0	0	2	1	3	4	3	6	4	2	8	1	2	1
C90	Multiple myeloma	16	0	0	0	0	0	0	0	0	1	2	3	4	1	2	0	2	0	1
C91-C95	Leukemia	30	2	3	0	1	1	2	3	2	3	3	2	2	1	2	2	1	0	0
Total		912	4	3	2	2	16	13	20	19	34	64	73	104	123	138	121	86	44	46

2023 HOSPITAL-BASED CANCER REGISTRY ANNUAL REPORT



● FEMALE ●

TABLE 64	DISTRIBUTION OF NEW CANCER IN MALE BY AGE - GROUP : 2023																				
ICD_10	Site	Age	0	5	10	15	20	25	30	35	40	45	50	55	60	65	70	75	80	85	
		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	
		Total	4	9	14	19	24	29	34	39	44	49	54	59	64	69	74	79	84		
C00-C08	Lip & Oral cavity	12	0	0	0	0	0	1	0	1	1	2	1	1	1	0	4	0	0	0	
C01,C05,C10	Oropharynx	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	
C09	Tonsil	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	
C11	Nasopharynx	5	0	0	0	0	0	0	0	0	2	1	0	1	1	0	0	0	0	0	
C16	Stomach	14	0	0	0	0	0	1	0	1	0	2	0	1	2	2	2	1	1	1	
C17	Small intestine	3	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0	0	
C18-C20	Colon and Rectum	102	0	0	0	0	0	1	1	5	6	5	12	12	12	11	10	11	10	6	
C21	Anus	7	0	0	0	0	0	0	0	1	1	0	1	0	0	2	0	1	0	1	
C22	Liver and Bile ducts	28	0	0	0	0	0	0	0	2	1	1	3	3	3	2	3	3	6	1	
C23-C24	Gallbladder	13	0	0	0	0	0	0	0	0	1	0	1	0	3	3	1	1	1	2	
C25	Pancreas	18	0	0	0	0	0	0	0	1	1	0	1	1	4	3	1	2	2	2	
C30-C31	Nose, sinuses etc	3	0	0	0	0	0	0	1	0	0	0	1	0	1	0	0	0	0	0	
C33-C34	Trachea, bronchus, lung	88	0	0	0	0	0	1	2	1	1	10	7	11	6	21	9	4	9	6	
C37-C39	Other thoracic organs	4	0	0	0	0	1	0	0	0	0	0	1	0	0	1	0	0	0	1	
C40-C41	Bone	8	0	0	1	0	0	2	2	0	0	0	0	2	0	0	1	0	0	0	
C43-C44	Melanoma of skin	22	0	0	0	0	0	1	2	0	0	0	1	3	3	0	3	2	5	2	
C45-C49	Mesothelioma	13	0	0	0	0	0	0	0	2	2	2	2	1	0	1	1	1	1	0	
C50	Breast	187	0	0	0	0	2	1	2	12	18	29	23	25	23	22	15	6	7	2	
C51-C52, C57	Female genital organs	7	0	0	0	0	0	0	1	0	1	1	0	1	0	1	0	1	0	1	
C53, C54, C55	Uterus	59	0	0	0	0	0	3	4	8	13	8	4	8	4	3	3	1	0	0	
C56	Ovary	51	0	0	0	0	0	1	1	0	0	10	4	11	7	7	6	3	1	0	
C64-C66	Kidney & Ureter	33	0	0	0	0	0	3	3	1	4	2	4	7	5	1	1	1	0	1	
C67	Bladder	20	0	0	1	0	0	0	0	0	0	0	6	3	1	3	1	2	1	2	
C71-C72	Brain	11	0	0	0	0	0	0	0	0	0	1	0	1	2	3	2	0	1	1	
C73	Thyroid gland	7	0	1	1	0	0	0	0	0	0	1	1	1	1	0	1	0	0	0	
C74	Adrenal gland	118	0	0	0	1	5	11	12	8	20	10	16	13	4	6	8	2	2	0	
C80	Without unspecified	2	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	
C81	Hodgkin's disease	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C82 -C85	Non-Hodgkin lymphoma	36	0	0	0	1	0	0	1	0	4	1	3	4	4	4	9	2	2	1	
C90	Multiple myeloma	15	0	0	0	0	0	0	0	0	0	1	1	6	2	0	3	0	2	0	
C91-C95	Leukaemia	19	3	1	1	0	0	1	1	2	1	2	3	0	2	2	0	0	0	0	
C91-C95	other endocrine glands and relate structures	5	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	0	0	
Total		913	3	3	4	2	8	27	33	45	78	89	97	118	95	100	85	45	51	30	



TABLE 65 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2023

ICD-10	Code	Morphology Description	Number of cases		
			Male	Female	Total
C00-C08, C14	Lip & Oral cavity		20	12	32
C020	8070/3	Squamous cell carcinoma, NOS	1	0	1
C021	8070/3	Squamous cell carcinoma, NOS	1	2	3
C0211	8070/3	Squamous cell carcinoma, NOS	3	0	3
C022	8070/3	Squamous cell carcinoma, NOS	1	0	1
C023	8070/3	Squamous cell carcinoma, NOS	1	1	2
C024	8070/3	Squamous cell carcinoma, NOS	0	1	1
C028	8010/6	Carcinoma, metastatic, NOS	0	1	1
	8070/6	Squamous cell carcinoma, metastatic, NOS	0	1	1
C029	8070/3	Squamous cell carcinoma, NOS	2	4	6
C031	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
C040	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
C049	8070/3	Squamous cell carcinoma, NOS	1	0	1
C060	8090/3	Basal cell carcinoma, NOS	0	1	1
C0613	8070/3	Squamous cell carcinoma, NOS	1	0	1
C062	8070/3	Squamous cell carcinoma, NOS	1	0	1
C07	-	-	1	0	1
	8010/3	Carcinoma, NOS	1	1	2
	8070/3	Squamous cell carcinoma, NOS	1	0	1
C080	8010/3	Carcinoma, NOS	2	0	2
C089	8010/3	Carcinoma, NOS	1	0	1
C09	Tonsil		7	1	8
C090	8010/6	Carcinoma, metastatic, NOS	1	0	1
	8070/3	Squamous cell carcinoma, NOS	2	0	2
C099	8010/3	Carcinoma, NOS	1	0	1
	8070/3	Squamous cell carcinoma, NOS	3	1	4
C01, C05, C10	Oropharynx etc.		12	1	13
C01	8070/3	Squamous cell carcinoma, NOS	1	0	1
C050	8070/3	Squamous cell carcinoma, NOS	1	0	1
C051	8070/3	Squamous cell carcinoma, NOS	1	1	2
C109	8010/3	Carcinoma, NOS	2	0	2
	8010/6	Carcinoma, metastatic, NOS	2	0	2
	8070/3	Squamous cell carcinoma, NOS	3	0	3
C140	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
C11	Nasopharynx		13	5	18
C112	8800/6	Sarcoma, metastatic, NOS	1	0	1
C119	-	-	2	1	3
	8010/3	Carcinoma, NOS	6	0	6
	8070/3	Squamous cell carcinoma, NOS	1	1	2
	8070/6	Squamous cell carcinoma, metastatic, NOS	1	1	2
	8071/3	Squamous cell carcinoma, keratinizing, NOS	1	0	1
	8073/3	Squamous cell carcinoma, small cell, nonkeratinizing	1	2	3


TABLE 65 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2023

ICD-10	Code	Morphology Description	Number of cases		
			Male	Female	Total
C12	Pyriform sinus		2	0	2
C120	8070/3	Squamous cell carcinoma, NOS	1	0	1
C129	8070/3	Squamous cell carcinoma, NOS	1	0	1
C13	Hypopharynx		8	0	8
C131	8070/3	Squamous cell carcinoma, NOS	1	0	1
C132	8070/3	Squamous cell carcinoma, NOS	1	0	1
C138	8070/3	Squamous cell carcinoma, NOS	1	0	1
C139	-	-	1	0	1
	8070/3	Squamous cell carcinoma, NOS	3	0	3
	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
C15	Esophagus		16	0	16
C150	8010/3	Carcinoma, NOS	1	0	1
	8070/3	Squamous cell carcinoma, NOS	1	0	1
C151	8070/3	Squamous cell carcinoma, NOS	3	0	3
C152	8140/3	Adenocarcinoma, NOS	1	0	1
C153	8070/3	Squamous cell carcinoma, NOS	1	0	1
C154	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
C155	8010/3	Carcinoma, NOS	1	0	1
C159	8070/3	Squamous cell carcinoma, NOS	4	0	4
	8070/6	Squamous cell carcinoma, metastatic, NOS	3	0	3
C16	Stomach		14	14	28
C160	-	-	0	1	1
	8140/3	Adenocarcinoma, NOS	3	1	4
	8890/3	Leiomyosarcoma, NOS	0	1	1
C161	8140/3	Adenocarcinoma, NOS	1	0	1
C162	8140/3	Adenocarcinoma, NOS	2	1	3
	8140/6	Adenocarcinoma, metastatic, NOS	2	0	2
C163	8140/3	Adenocarcinoma, NOS	1	3	4
C165	8140/3	Adenocarcinoma, NOS	0	1	1
C166	8140/3	Adenocarcinoma, NOS	1	1	2
C169	-	-	1	0	1
	8010/3	Carcinoma, NOS	0	1	1
	8140/3	Adenocarcinoma, NOS	3	1	4
	8140/6	Adenocarcinoma, metastatic, NOS	0	2	2
	8246/6	Neuroendocrine carcinoma, metastatic, NOS	0	1	1
C17	Small intestine		1	3	4
C170	-	-	1	0	1
C171	8004/6	Malignant tumor, spindle cell type	0	1	1
C179	-	-	0	1	1
	8720/6	Malignant melanoma, metastatic, NOS	0	1	1



HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT

2023

TABLE 65 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2023

ICD-10	Code	Morphology Description	Number of cases		
			Male	Female	Total
C18-C20	Colon & Rectosigmoid junction & Rectum		147	102	249
C180	-	-	0	1	1
	8140/3	Adenocarcinoma, NOS	1	7	8
	8140/6	Adenocarcinoma, metastatic, NOS	2	0	2
	8480/6	Mucinous adenocarcinoma, metastatic	1	0	1
C181	-	-	0	1	1
	8140/3	Adenocarcinoma, NOS	1	1	2
	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1
C182	8140/3	Adenocarcinoma, NOS	3	3	6
	8140/6	Adenocarcinoma, metastatic, NOS	0	2	2
	8480/3	Mucinous adenocarcinoma	0	1	1
C183	8140/3	Adenocarcinoma, NOS	1	1	2
	8140/6	Adenocarcinoma, metastatic, NOS	3	0	3
C184	-	-	1	1	2
	8140/3	Adenocarcinoma, NOS	1	3	4
	8140/6	Adenocarcinoma, metastatic, NOS	5	1	6
C185	8140/3	Adenocarcinoma, NOS	3	1	4
	8140/6	Adenocarcinoma, metastatic, NOS	0	2	2
C186	8140/3	Adenocarcinoma, NOS	5	5	10
	8140/6	Adenocarcinoma, metastatic, NOS	2	0	2
C187	-	-	2	0	2
	8140/3	Adenocarcinoma, NOS	32	26	58
	8140/6	Adenocarcinoma, metastatic, NOS	18	6	24
	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1
C189	8140/3	Adenocarcinoma, NOS	3	3	6
	8140/6	Adenocarcinoma, metastatic, NOS	2	2	4
C19	-	-	1	0	1
	8140/3	Adenocarcinoma, NOS	4	3	7
	8140/6	Adenocarcinoma, metastatic, NOS	1	1	2
C20	-	-	6	2	8
	8010/3	Carcinoma, NOS	0	1	1
	8070/3	Squamous cell carcinoma, NOS	0	1	1
	8140/3	Adenocarcinoma, NOS	33	14	47
	8140/6	Adenocarcinoma, metastatic, NOS	14	11	25
	8574/3	Adenocarcinoma with neuroendocrine differentiation	1	0	1
	8802/6	Giant cell sarcoma, metastatic	1	0	1
C21	Anus & Anus canal		12	7	19
C210	8010/6	Carcinoma, metastatic, NOS	1	0	1
	8070/3	Squamous cell carcinoma, NOS	0	1	1
	8140/3	Adenocarcinoma, NOS	0	1	1
C211	8073/3	Squamous cell carcinoma, small cell, nonkeratinizing	0	1	1
	8140/3	Adenocarcinoma, NOS	2	0	2
C218	8010/6	Carcinoma, metastatic, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	7	3	10
	8140/6	Adenocarcinoma, metastatic, NOS	1	1	2


TABLE 65 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2023

ICD-10	Code		Morphology Description	Number of cases		
				Male	Female	Total
C22	Liver & Intrahepatic bile ducts		98	28	126	
C220	-	-	49	10	59	
	8010/3	Carcinoma, NOS	2	0	2	
	8010/6	Carcinoma, metastatic, NOS	2	0	2	
	8070/3	Squamous cell carcinoma, NOS	0	1	1	
	8140/3	Adenocarcinoma, NOS	3	2	5	
	8140/6	Adenocarcinoma, metastatic, NOS	2	0	2	
	8170/3	Hepatocellular carcinoma, NOS	23	9	32	
	8170/6	Hepatocellular carcinoma, metastatic, NOS	3	0	3	
	8180/3	Combined hepatocellular carcinoma and cholangiocarcinoma	1	0	1	
	8970/3	Hepatoblastoma	1	0	1	
C221	-	-	3	0	3	
	8140/3	Adenocarcinoma, NOS	2	2	4	
	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1	
	8170/3	Hepatocellular carcinoma, NOS	1	0	1	
	8180/3	Combined hepatocellular carcinoma and cholangiocarcinoma	1	0	1	
C229	-	-	4	3	7	
	8140/6	Adenocarcinoma, metastatic, NOS	1	0	1	
C23-C24	Gall bladder & Unspecified parts of biliary tract		13	13	26	
C23	8140/3	Adenocarcinoma, NOS	2	1	3	
	8140/6	Adenocarcinoma, metastatic, NOS	0	2	2	
C240	-	-	1	0	1	
	8140/3	Adenocarcinoma, NOS	1	1	2	
	8140/6	Adenocarcinoma, metastatic, NOS	1	3	4	
	8480/3	Mucinous adenocarcinoma	1	0	1	
C241	8140/3	Adenocarcinoma, NOS	4	3	7	
	8140/6	Adenocarcinoma, metastatic, NOS	1	2	3	
	8160/3	Cholangiocarcinoma	0	1	1	
C249	8140/3	Adenocarcinoma, NOS	1	0	1	
	8140/6	Adenocarcinoma, metastatic, NOS	1	0	1	



HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT

2023

TABLE 65 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2023

ICD-10	Code	Morphology Description	Number of cases		
			Male	Female	Total
C25	Pancreas		22	18	40
C250	-	-	0	1	1
	8010/3	Carcinoma, NOS	2	1	3
	8010/6	Carcinoma, metastatic, NOS	0	1	1
	8140/3	Adenocarcinoma, NOS	5	2	7
	8140/6	Adenocarcinoma, metastatic, NOS	2	1	3
	8246/3	Neuroendocrine carcinoma, NOS	1	0	1
C251	8140/3	Adenocarcinoma, NOS	0	2	2
	8140/6	Adenocarcinoma, metastatic, NOS	2	2	4
C252	-	-	1	0	1
	8140/6	Adenocarcinoma, metastatic, NOS	2	2	4
C253	8140/3	Adenocarcinoma, NOS	2	0	2
	8140/6	Adenocarcinoma, metastatic, NOS	0	2	2
	8246/3	Neuroendocrine carcinoma, NOS	0	1	1
	8806/6	Desmoplastic small round cell tumor, metastatic	2	0	2
C254	8806/6	Desmoplastic small round cell tumor, metastatic	2	0	2
	8806/6	Desmoplastic small round cell tumor, metastatic	2	0	2
C257	-	-	1	1	2
	9014/3	Serous adenocarcinofibroma	1	0	1
C259	8010/3	Carcinoma, NOS	1	0	1
	8140/6	Adenocarcinoma, metastatic, NOS	0	2	2
C30-C31	Nasal cavity & Accessory sinuses		7	3	10
C300	8010/3	Carcinoma, NOS	2	2	4
	8070/3	Squamous cell carcinoma, NOS	0	1	1
	8720/3	Malignant melanoma, NOS	1	0	1
C310	8010/3	Carcinoma, NOS	1	0	1
	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8430/3	Mucoepidermoid carcinoma	1	0	1
	8852/3	Myxoid Liposarcoma	1	0	1
C32	Larynx		11	0	11
C320	8070/3	Squamous cell carcinoma, NOS	4	0	4
C321	8070/3	Squamous cell carcinoma, NOS	2	0	2
	8071/3	Squamous cell carcinoma, keratinizing, NOS	1	0	1
C323	8070/3	Squamous cell carcinoma, NOS	1	0	1
C329	8070/3	Squamous cell carcinoma, NOS	3	0	3


TABLE 65 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2023

ICD-10	Code	Morphology Description	Number of cases		
			Male	Female	Total
C33-C34	Trachea, Bronchus & Lung		108	88	196
C340	8010/3	Carcinoma, NOS	2	1	3
	8010/6	Carcinoma, metastatic, NOS	1	2	3
	8041/6	Small cell carcinoma, metastatic, NOS	1	0	1
	8046/3	Non-small cell carcinoma	4	1	5
	8046/6	Non-small cell carcinoma, metastatic	1	2	3
	8140/3	Adenocarcinoma, NOS	4	4	8
	8140/6	Adenocarcinoma, metastatic, NOS	1	3	4
	8480/3	Mucinous adenocarcinoma	0	1	1
C341	-	-	2	0	2
	8010/3	Carcinoma, NOS	2	1	3
	8046/3	Non-small cell carcinoma	4	1	5
	8046/6	Non-small cell carcinoma, metastatic	2	0	2
	8070/3	Squamous cell carcinoma, NOS	2	0	2
	8140/3	Adenocarcinoma, NOS	5	5	10
	8140/6	Adenocarcinoma, metastatic, NOS	6	10	16
	8480/3	Mucinous adenocarcinoma	0	1	1
C342	8046/3	Non-small cell carcinoma	1	0	1
	8140/6	Adenocarcinoma, metastatic, NOS	0	3	3
C343	8010/3	Carcinoma, NOS	1	0	1
	8010/6	Carcinoma, metastatic, NOS	0	1	1
	8041/6	Small cell carcinoma, metastatic, NOS	0	1	1
	8046/3	Non-small cell carcinoma	0	2	2
	8046/6	Non-small cell carcinoma, metastatic	1	1	2
	8070/3	Squamous cell carcinoma, NOS	2	0	2
	8140/3	Adenocarcinoma, NOS	1	2	3
	8140/6	Adenocarcinoma, metastatic, NOS	5	2	7
C348	8010/6	Carcinoma, metastatic, NOS	1	0	1
C349	-	-	0	1	1
	8010/3	Carcinoma, NOS	2	1	3
	8010/6	Carcinoma, metastatic, NOS	6	0	6
	8010/6	Carcinoma, metastatic, NOS	0	1	1
	8046/3	Non-small cell carcinoma	3	3	6
	8046/6	Non-small cell carcinoma, metastatic	5	9	14
	8070/3	Squamous cell carcinoma, NOS	2	0	2
	8070/6	Squamous cell carcinoma, metastatic, NOS	3	1	4
	8140/3	Adenocarcinoma, NOS	14	9	23
	8140/6	Adenocarcinoma, metastatic, NOS	23	19	42
	8246/3	Neuroendocrine carcinoma, NOS	1	0	1



HOSPITAL-BASED CANCER REGISTRY 2023

ANNUAL REPORT

TABLE 65 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2023

ICD-10	Code	Morphology Description	Number of cases		
			Male	Female	Total
C37-C38	Intrathoracic organs		2	4	6
C37	-	-	0	1	1
	8010/3	Carcinoma, NOS	1	0	1
	8070/3	Squamous cell carcinoma, NOS	0	1	1
C381	9085/6	Mixed germ cell tumor, metastatic	1	0	1
C383	8801/3	Spindle cell sarcoma	0	1	1
C384	8010/6	Carcinoma, metastatic, NOS	0	1	1
C40-C41	Bone & Articular cartilage		9	8	17
C400	-	-	1	0	1
C401	-	-	0	3	3
C402	-	-	0	1	1
	8801/3	Spindle cell sarcoma	0	1	1
	8850/3	Liposarcoma, NOS	1	0	1
	9180/3	Osteosarcoma, NOS	3	1	4
	9220/3	Chondrosarcoma, NOS	0	1	1
	9231/3	Chondroblastoma, malignant	1	0	1
	9261/3	Adamantinoma of long bones	0	1	1
C411	8070/3	Squamous cell carcinoma, NOS	1	0	1
C413	8020/3	Carcinoma, undifferentiated, NOS	1	0	1
C419	8801/3	Spindle cell sarcoma	1	0	1
C43-C44	Skin		24	22	46
C434	8090/3	Basal cell carcinoma, NOS	0	1	1
	8720/3	Malignant melanoma, NOS	0	1	1
C435	8720/3	Malignant melanoma, NOS	0	2	2
C436	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8720/3	Malignant melanoma, NOS	1	0	1
C437	8720/3	Malignant melanoma, NOS	1	0	1
C439	8090/6	Basal cell carcinoma, metastatic, NOS	1	0	1
	8720/3	Malignant melanoma, NOS	0	1	1
	8720/6	Malignant melanoma, metastatic, NOS	0	1	1
	8744/3	Acral lentiginous melanoma, malignant	1	0	1
C440	8070/3	Squamous cell carcinoma, NOS	1	0	1
C442	-	-	0	1	1
	8070/3	Squamous cell carcinoma, NOS	1	1	2
C443	8070/3	Squamous cell carcinoma, NOS	0	1	1
	8090/3	Basal cell carcinoma, NOS	6	4	10
	8480/3	Mucinous adenocarcinoma	1	0	1
C444	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8090/3	Basal cell carcinoma, NOS	1	1	2
C445	8070/3	Squamous cell carcinoma, NOS	1	1	2
C447	8051/3	Verrucous carcinoma, NOS	1	0	1
C449	8051/3	Verrucous carcinoma, NOS	0	1	1
	8070/3	Squamous cell carcinoma, NOS	1	1	2
	8090/3	Basal cell carcinoma, NOS	4	5	9
	8832/3	Dermatofibrosarcoma, NOS	1	0	1



TABLE 65 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2023					
ICD-10	Code	Morphology Description	Number of cases		
			Male	Female	Total
C45 – C49	Mesothelial & Soft tissue		17	13	30
C480	-	-	0	1	1
	8010/3	Carcinoma, NOS	0	1	1
	8858/3	Dedifferentiated liposarcoma	0	1	1
	8890/3	Leiomyosarcoma, NOS	0	1	1
	8890/6	Leiomyosarcoma, metastatic, NOS	0	1	1
C490	8070/3	Squamous cell carcinoma, NOS	2	0	2
C491	8800/3	Sarcoma, NOS	1	0	1
	8801/3	Spindle cell sarcoma	0	1	1
C492	-	-	2	0	2
	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8805/3	Undifferentiated sarcoma	1	0	1
	8806/3	Desmoplastic small round cell tumor	1	0	1
	8821/3	Invasive fibroma	1	0	1
	8850/3	Liposarcoma, NOS	1	0	1
	8851/3	Liposarcoma, well differentiated	0	1	1
	8852/3	Myxoid Liposarcoma	0	1	1
	8858/3	Dedifferentiated liposarcoma	0	1	1
C493	8801/3	Spindle cell sarcoma	1	0	1
C494	8890/3	Leiomyosarcoma, NOS	1	0	1
	8890/6	Leiomyosarcoma, metastatic, NOS	0	1	1
C496	8890/3	Leiomyosarcoma, NOS	1	0	1
C499	-	-	2	2	4
	8801/6	Spindle cell sarcoma, metastatic	1	0	1
	8832/3	Dermatofibrosarcoma, NOS	1	0	1
	8852/6	Myxoid Liposarcoma, metastatic	0	1	1
C50	Breast		2	187	189
C500	8010/6	Carcinoma, metastatic, NOS	0	1	1
	8500/3	Infiltrating duct carcinoma, NOS	1	5	6
C501	8010/6	Carcinoma, metastatic, NOS	0	1	1
	8140/3	Adenocarcinoma, NOS	0	1	1
	8500/3	Infiltrating duct carcinoma, NOS	0	4	4
C502	8500/3	Infiltrating duct carcinoma, NOS	0	6	6
	8500/6	Infiltrating duct carcinoma, metastatic, NOS	0	1	1
C503	8500/3	Infiltrating duct carcinoma, NOS	0	3	3
C504	8500/3	Infiltrating duct carcinoma, NOS	0	11	11
C505	8500/3	Infiltrating duct carcinoma, NOS	0	1	1
C509	-	-	0	3	3
	8010/3	Carcinoma, NOS	0	4	4
	8010/6	Carcinoma, metastatic, NOS	0	1	1
	8050/3	Papillary carcinoma, NOS	0	1	1
	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1
	8500/3	Infiltrating duct carcinoma, NOS	1	124	125
	8500/6	Infiltrating duct carcinoma, metastatic, NOS	0	16	16
	8540/3	Paget disease, mammary	0	2	2
	8541/3	Paget disease and infiltrating duct carcinoma of breast	0	1	1



HOSPITAL-BASED CANCER REGISTRY 2023

ANNUAL REPORT

TABLE 65 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2023

ICD-10	Code	Morphology Description	Number of cases		
			Male	Female	Total
C51,C52,C57	Female genital organs		0	7	7
C510	8070/3	Squamous cell carcinoma, NOS	0	1	1
C519	8010/3	Carcinoma, NOS	0	2	2
	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1
	8720/3	Malignant melanoma, NOS	0	1	1
C52	8070/3	Squamous cell carcinoma, NOS	0	1	1
C58	-	-	0	1	1
C53	Cervix		0	59	59
C530	8010/3	Carcinoma, NOS	0	1	1
	8070/3	Squamous cell carcinoma, NOS	0	1	1
	8140/3	Adenocarcinoma, NOS	0	10	10
	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1
C531	8010/3	Carcinoma, NOS	0	1	1
	8070/3	Squamous cell carcinoma, NOS	0	21	21
	8071/3	Squamous cell carcinoma, keratinizing, NOS	0	2	2
	8072/3	Squamous cell carcinoma, large cell, nonkeratinizing, NOS	0	1	1
	8073/3	Squamous cell carcinoma, small cell, nonkeratinizing	0	15	15
C539	-	-	0	2	2
	8010/3	Carcinoma, NOS	0	1	1
	8070/3	Squamous cell carcinoma, NOS	0	1	1
	8140/3	Adenocarcinoma, NOS	0	1	1
	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1
C54, C55	Uterus		0	51	51
C541	-	-	0	1	1
	8010/3	Carcinoma, NOS	0	17	17
	8010/6	Carcinoma, metastatic, NOS	0	1	1
	8140/3	Adenocarcinoma, NOS	0	12	12
	8140/6	Adenocarcinoma, metastatic, NOS	0	2	2
	8380/3	Endometrioid adenocarcinoma, NOS	0	8	8
	8441/3	Serous cystadenocarcinoma, NOS	0	1	1
	8980/3	Carcinosarcoma, NOS	0	1	1
	8981/3	Carcinosarcoma, embryonal	0	1	1
C543	8380/3	Endometrioid adenocarcinoma, NOS	0	1	1
C548	8140/3	Adenocarcinoma, NOS	0	1	1
C549	8310/3	Clear cell adenocarcinoma, NOS	0	1	1
	8380/3	Endometrioid adenocarcinoma, NOS	0	2	2
C55	8140/3	Adenocarcinoma, NOS	0	1	1
	8720/6	Malignant melanoma, metastatic, NOS	0	1	1


TABLE 65 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2023

ICD-10	Code	Morphology Description	Number of cases		
			Male	Female	Total
C56	Ovary		0	33	33
C56	-	-	0	3	3
	8010/3	Carcinoma, NOS	0	5	5
	8010/6	Carcinoma, metastatic, NOS	0	1	1
	8073/3	Squamous cell carcinoma, small cell, nonkeratinizing	0	1	1
	8140/3	Adenocarcinoma, NOS	0	4	4
	8140/6	Adenocarcinoma, metastatic, NOS	0	3	3
	8310/3	Clear cell adenocarcinoma, NOS	0	7	7
	8380/3	Endometrioid adenocarcinoma, NOS	0	4	4
	8441/3	Serous cystadenocarcinoma, NOS	0	2	2
	8441/6	Serous cystadenocarcinoma, metastatic, NOS	0	1	1
	8480/3	Mucinous adenocarcinoma	0	1	1
	9560/3	Neurilemoma, malignant	0	1	1
C60,C62,C63	Male genital organs		10	0	10
C600	-	-	1	0	1
	8070/3	Squamous cell carcinoma, NOS	3	0	3
C602	8070/3	Squamous cell carcinoma, NOS	1	0	1
C621	9085/3	Mixed germ cell tumor	1	0	1
C629	8010/3	Carcinoma, NOS	1	0	1
	8631/6	Sertoli-Leydig cell tumor, sarcomatoid, metastatic	1	0	1
	9080/3	Teratoma, malignant, NOS	1	0	1
	9085/3	Mixed germ cell tumor	1	0	1
C61	Prostate gland		146	0	146
C61	-	-	1	0	1
	8140/3	Adenocarcinoma, NOS	123	0	123
	8140/6	Adenocarcinoma, metastatic, NOS	22	0	22
C64-C66	Kidney, Renal pelvis & Ureter		22	20	42
C64	-	-	2	1	3
	8010/3	Carcinoma, NOS	0	1	1
	8010/6	Carcinoma, metastatic, NOS	1	2	3
	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1
	8310/3	Clear cell adenocarcinoma, NOS	2	2	4
	8312/3	Renal cell carcinoma, NOS	11	8	19
	8312/6	Renal cell carcinoma, metastatic, NOS	4	1	5
C65	8120/3	Transitional cell carcinoma, NOS	0	1	1
	8312/3	Renal cell carcinoma, NOS	0	1	1
C66	8010/3	Carcinoma, NOS	1	1	2
	8120/3	Transitional cell carcinoma, NOS	1	0	1
	8130/3	Transitional cell carcinoma, micropapillary	0	1	1



HOSPITAL-BASED CANCER REGISTRY 2023

ANNUAL REPORT

TABLE 65 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2023

ICD-10	Code	Morphology Description	Number of cases		
			Male	Female	Total
C67	Bladder		34	11	45
C670	8010/3	Carcinoma, NOS	2	0	2
	8130/3	Transitional cell carcinoma, micropapillary	3	2	5
	8130/6	Transitional cell carcinoma, micropapillary, metastatic	0	1	1
C671	8130/3	Transitional cell carcinoma, micropapillary	4	1	5
C672	-	-	1	0	1
	8010/3	Carcinoma, NOS	0	1	1
	8010/6	Carcinoma, metastatic, NOS	1	0	1
	8130/3	Transitional cell carcinoma, micropapillary	1	1	2
C673	8010/3	Carcinoma, NOS	1	0	1
C674	-	-	2	0	2
	8010/3	Carcinoma, NOS	3	2	5
	8010/6	Carcinoma, metastatic, NOS	1	0	1
	8120/3	Transitional cell carcinoma, NOS	0	1	1
	8130/3	Transitional cell carcinoma, micropapillary	1	0	1
C678	8120/3	Transitional cell carcinoma, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	1	0	1
C679	-	-	1	1	2
	8010/3	Carcinoma, NOS	4	1	5
	8120/3	Transitional cell carcinoma, NOS	1	0	1
	8120/6	Transitional cell carcinoma, metastatic, NOS	1	0	1
	8130/3	Transitional cell carcinoma, micropapillary	4	0	4
	8130/6	Transitional cell carcinoma, micropapillary, metastatic	1	0	1
C69-C70	Eye & Meninges		1	0	1
C699	8070/3	Squamous cell carcinoma, NOS	1	0	1
C71-C72	Brain		10	7	17
C711	9400/3	Astrocytoma, NOS	1	0	1
	9530/3	Meningioma, malignant	0	1	1
C718	-	-	0	1	1
C719	-	-	2	1	3
	8720/3	Malignant melanoma, NOS	0	1	1
	9085/3	Mixed germ cell tumor	2	0	2
	9380/3	Glioma, malignant	5	2	7
C720	9391/3	Ependymoma, NOS	0	1	1


TABLE 65 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2023

ICD-10	Code	Morphology Description	Number of cases		
			Male	Female	Total
C73	Thyroid gland		33	118	151
C73	-	-	1	0	1
	8010/3	Carcinoma, NOS	2	4	6
	8010/6	Carcinoma, metastatic, NOS	0	2	2
	8050/3	Papillary carcinoma, NOS	21	92	113
	8050/6	Papillary carcinoma, metastatic, NOS	1	2	3
	8260/3	Papillary adenocarcinoma, NOS	5	7	12
	8290/3	Oxyphilic adenocarcinoma	0	1	1
	8335/3	Follicular carcinoma, minimally invasive	2	3	5
	8340/3	Papillary carcinoma, follicular variant	1	1	2
	8341/3	Papillary microcarcinoma	0	5	5
	8507/3	Intraductal micropapillary carcinoma	0	1	1
C74	Adrenal gland		2	0	2
C749	9500/3	Neuroblastoma, NOS	1	0	1
C751	9064/3	Germinoma	1	0	1
C75-C79	Other endocrine glands and relate structures		1	5	6
C760	8070/3	Squamous cell carcinoma, NOS	0	1	1
	8090/3	Basal cell carcinoma, NOS	0	1	1
C770	8010/6	Carcinoma, metastatic, NOS	0	1	1
	8013/6	Large cell neuroendocrine carcinoma, metastatic	1	0	1
C779	8010/6	Carcinoma, metastatic, NOS	0	2	2
C80	Without specification of site		2	2	4
C800	8010/3	Carcinoma, NOS	1	0	1
	8010/6	Carcinoma, metastatic, NOS	0	1	1
	8070/3	Squamous cell carcinoma, NOS	1	0	1
C809	8010/6	Carcinoma, metastatic, NOS	0	1	1
C81	Hodgkin's lymphoma		2	1	3
C811	9596/3	Composite Hodgkin and non-Hodgkin lymphoma	1	0	1
C819	9650/3	Hodgkin lymphoma, NOS	0	1	1
	9667/3	Hodgkin lymphoma, nodular sclerosis, grade 2	1	0	1



HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT

2023

TABLE 65	DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2023				
ICD-10	Code	Morphology	Number of cases		
		Description	Male	Female	Total
C82-C88	Non - Hodgkin's lymphoma		38	36	74
C823	9670/3	Malignant lymphoma, small B lymphocytic, NOS	0	1	1
C829	9596/3	Composite Hodgkin and non-Hodgkin lymphoma	0	1	1
	9596/3	Composite Hodgkin and non-Hodgkin lymphoma	0	1	1
C830	9596/3	Composite Hodgkin and non-Hodgkin lymphoma	1	2	3
C833	-	-	1	0	1
	9596/3	Composite Hodgkin and non-Hodgkin lymphoma	9	4	13
	9680/3	Malignant lymphoma, large B-cell, diffuse, NOS	7	5	12
	9680/6	Malignant lymphoma, large B-cell, diffuse, metastatic, NOS	0	2	2
	9684/3	Malignant lymphoma, large B-cell, diffuse, immunoblastic, NOS	1	0	1
	9695/3	Follicular lymphoma, grade 1	0	2	2
C838	9596/3	Composite Hodgkin and non-Hodgkin lymphoma	1	0	1
C839	9596/3	Composite Hodgkin and non-Hodgkin lymphoma	0	1	1
C84	9702/3	Mature T-cell lymphoma, NOS	1	0	1
C840	9827/3	Adult T-cell leukemia/lymphoma	1	0	1
C844	9702/3	Mature T-cell lymphoma, NOS	2	2	4
C847	9680/3	Malignant lymphoma, large B-cell, diffuse, NOS	0	1	1
C85	9680/3	Malignant lymphoma, large B-cell, diffuse, NOS	0	1	1
C851	9596/3	Composite Hodgkin and non-Hodgkin lymphoma	2	2	4
	9680/3	Malignant lymphoma, large B-cell, diffuse, NOS	2	1	3
C852	9680/3	Malignant lymphoma, large B-cell, diffuse, NOS	0	1	1
C859	-	-	1	0	1
	9596/3	Composite Hodgkin and non-Hodgkin lymphoma	7	4	11
	9680/3	Malignant lymphoma, large B-cell, diffuse, NOS	0	2	2
	9680/6	Malignant lymphoma, large B-cell, diffuse, metastatic, NOS	0	1	1
	9699/3	Composite Hodgkin and non-Hodgkin lymphoma	1	0	1
C860	9699/3	Composite Hodgkin and non-Hodgkin lymphoma	0	1	1
C884	9596/3	Composite Hodgkin and non-Hodgkin lymphoma	1	0	1
	9680/3	Malignant lymphoma, large B-cell, diffuse, NOS	0	1	1



TABLE 65		DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2023				
ICD-10	Code		Morphology Description	Number of cases		
				Male	Female	Total
C90	Multiple myeloma		16	15	31	
C900	-	-	2	3	5	
	9732/3	Multiple myeloma	14	10	24	
	9732/6	Multiple myeloma, metastatic	0	2	2	
C91-C95	Leukemia		30	19	49	
C910	9835/3	Precursor cell lymphoblastic leukemia, NOS	7	5	12	
C911	9823/3	B-cell chronic lymphocytic leukemia/small lymphoma	2	1	3	
C913	9861/3	Acute myeloid leukemia, NOS	0	1	1	
C920	9801/3	Acute leukemia, NOS	1	0	1	
	9835/3	Precursor cell lymphoblastic leukemia, NOS	1	0	1	
	9861/3	Acute myeloid leukemia, NOS	12	8	20	
C921	9863/3	Chronic myeloid leukemia, NOS	1	2	3	
C923	9861/3	Acute myeloid leukemia, NOS	1	0	1	
C925	9861/3	Acute myeloid leukemia, NOS	2	1	3	
C946	9590/3	Malignant lymphoma, NOS	1	0	1	
	9861/3	Acute myeloid leukemia, NOS	1	0	1	
C950	9860/3	Myeloid leukemia, NOS	1	0	1	
C966	9754/3	Langerhans cell histiocytosis, disseminated	0	1	1	





HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT

2023

NEW CANCER PATIENTS 2019-2023

TABLE 66 NUMBER OF NEW CANCER PATIENTS : 2019 – 2023						
Years	New cancer case	Case	Male		Female	
	Number	Percent	Number	Percent	Number	Percent
2562 (2019)	1,720	20.52	885	21.12	835	19.92
2563 (2020)	1,608	19.19	800	19.09	808	19.28
2564 (2021)	1,526	18.21	771	18.40	755	18.01
2565 (2022)	1,702	20.31	822	19.62	880	21.00
2566 (2023)	1,825	21.78	912	21.77	913	21.78
Total	8,381	100.00	4,190	100.00	4,191	100.00

TABLE 67 DISTRIBUTION OF NEW CANCER PATIENTS BY FOLLOW UP AND GENDER: 2019-2023						
Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	2,466	58.9	3,059	73.0	5,525	65.9
Deaths	1,724	41.1	1,132	27.0	2,856	34.1
Total	4,190	100.0	4,191	100.0	8,381	100.0

Survey: 30 June 2024





TABLE 68 THE LEADING PRIMARY SITES OF NEW CANCER BY GENDER: 2019-2023							
Ordinal	Primary site	Male		Female		Total	
		Number	Percent	Number	Percent	Number	Percent
1	Colon and Rectum	644	15.4	445	10.6	1089	13.0
2	Breast	12	0.3	1010	24.1	1022	12.2
3	Trachea, bronchus and lung	566	13.5	386	9.2	952	11.4
4	Liver and intrahepatic bile ducts	455	10.9	131	3.1	586	7.0
5	Thyroid gland	111	2.6	461	11.0	572	6.8
6	Prostate gland	522	12.5	0	0.0	522	6.2
7	Non-Hodgkin's lymphoma	201	4.8	182	4.3	383	4.6
8	Cervix	0	0.0	244	5.8	244	2.9
9	leukemia	142	3.4	98	2.3	240	2.9
10	Skin	110	2.6	112	2.7	222	2.6

Survey: 30 June 2024

TABLE 69 THE LEADING PRIMARY SITES OF NEW CANCER BY FOLLOW UP AND GENDER: 2019-2023						
Ordinal	Primary site	Alive		Deaths		Total
		Male	Female	Male	Female	
1	Colon and Rectum	434	309	210	136	1089
2	Breast	11	857	1	153	1022
3	Trachea, bronchus and lung	213	200	353	186	952
4	Liver and intrahepatic bile ducts	202	54	253	77	586
5	Thyroid gland	99	441	12	20	572
6	Prostate gland	540	0	88	0	628
7	Non-Hodgkin's lymphoma	130	129	71	53	383
8	Cervix	0	180	0	64	244
9	leukemia	70	56	72	42	240
10	Skin	84	86	26	26	222

Survey: 30 June 2024



TABLE 70 THE 60 MONTHS SURVIVAL TIME (MEDIAN) TOP 6 BY GENDER IN 2019 - 2023			
Ordinal	Primary site	Male	Female
1	Colon and Rectum	11.34	11.84
2	Breast	10.00	5.60
3	Trachea, bronchus and lung	4.74	6.43
4	Liver and intrahepatic bile ducts	4.24	4.42
5	Thyroid gland	8.12	10.39
6	Prostate gland	5.61	-

Survey: 30 June 2024

FIGURE 32: THE 60 MONTHS SERVIVAL RATE (TOP 6) IN 2019 – 2023







FIGURE 33: THE 60 MONTHS SURVIVAL RATE (TOP 6) BY MALE IN 2019 – 2023








HOSPITAL-BASED CANCER REGISTRY
ANNUAL REPORT

2023

FIGURE 34: THE 60 MONTHS SURVIVAL RATE (TOP 6) BY FEMALE IN 2019–2023



Phramongkutklao Hospital 315 Ratchawithi Rd, Bangkok 10400 Thailand.





PHRAMONGKUTKLAO HOSPITAL

EXCELLENT CENTER
OF CANCER CARE

2023

Oncology Unit and Epidemiology Unit,
Phramongkutklao Hospital.

315 Ratchawithi Road, Bangkok 10400, Thailand.

Tel. : + 66 2763 3925, + 66 2763 3047

Email : ceupmk@hotmail.com

Website : <http://ceu.pmk.ac.th>